Ci    O
,    O
Si    O
:    O
Trigonometric    B-Calculation105802185
integral    I-Calculation105802185
,    O
Ei    O
:    O
Exponential    B-Calculation105802185
integral    I-Calculation105802185
,    O
li    O
:    O
Logarithmic    B-Calculation105802185
integral    I-Calculation105802185
function    I-Calculation105802185
,    O
erf    O
:    O
Error    O
function    O

:    O
(    O
see    O
sinc    O
function    O
and    O
Sine    B-Calculation105802185
integral    I-Calculation105802185
)    O

its    O
integral    O
,    O
the    O
sine    B-Calculation105802185
integral    I-Calculation105802185
–    O
thus    O
also    O
features    O
oscillations    O
,    O
as    O
illustrated    O
at    O
right    O
.    O

The    O
Sine    B-Calculation105802185
integral    I-Calculation105802185
for    O
positive    O
values    O
,    O
exhibiting    O
oscillation    O
.    O

A    O
drink    O
made    O
from    O
coffee    O
husks    O
called    O
qishr    B-Calculation105802185
is    O
also    O
enjoyed    O
.    O

Rule    B-Calculation105802185
of    I-Calculation105802185
three    I-Calculation105802185
(statistics)    I-Calculation105802185
,    O
a    O
similar    O
result    O
for    O
the    O
Bernoulli    O
distribution    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
methylamine    O
and    O
L    O
-    O
glutamate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
NH3    O
and    O
N-methyl-L-glutamate    B-Calculation105802185
.    O

Proinsulin    O
undergoes    O
maturation    O
into    O
active    O
insulin    O
through    O
the    O
action    O
of    O
cellular    O
endopeptidases    O
known    O
as    O
prohormone    O
convertases    O
(    O
PC1    O
and    O
PC2    O
)    O
,    O
as    O
well    O
as    O
the    O
exoprotease    O
carboxypeptidase    O
E.    O
The    O
endopeptidases    O
cleave    O
at    O
2    O
positions    O
,    O
releasing    O
a    O
fragment    O
called    O
the    O
C-peptide    B-Calculation105802185
,    O
and    O
leaving    O
2    O
peptide    O
chains    O
,    O
the    O
B-    O
and    O
A-    O
chains    O
,    O
linked    O
by    O
2    O
disulfide    O
bonds    O
.    O

The    O
C-peptide    B-Calculation105802185
is    O
the    O
central    O
portion    O
of    O
proinsulin    O
,    O
and    O
the    O
primary    O
sequence    O
of    O
proinsulin    O
goes    O
in    O
the    O
order    O
"    O
B    O
-    O
C    O
-    O
A    O
"    O
(    O
the    O
B    O
and    O
A    O
chains    O
were    O
identified    O
on    O
the    O
basis    O
of    O
mass    O
and    O
the    O
C    O
-    O
peptide    O
was    O
discovered    O
later    O
)    O
.    O

Of    O
these    O
markers    O
,    O
nPOD    O
tests    O
for    O
C-Peptide    B-Calculation105802185
,    O
autoantibodies    O
,    O
and    O
HLA    O
.    O

Finally    O
,    O
proinsulin    O
is    O
converted    O
into    O
the    O
bioactive    O
hormone    O
insulin    O
by    O
removal    O
of    O
the    O
C-peptide    B-Calculation105802185
.    O

:    O
acetyl    O
-    O
CoA    O
+    O
carnitine    O
CoA    O
+    O
acetylcarnitine    B-Calculation105802185

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
and    O
carnitine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
O    O
-    O
acetylcarnitine    B-Calculation105802185
.    O

VidaLinux    B-Calculation105802185

Pooled    B-Calculation105802185
degrees    I-Calculation105802185
of    I-Calculation105802185
freedom    I-Calculation105802185

Streptozotocin    B-Calculation105802185

Streptozotocin    B-Calculation105802185
is    O
used    O
in    O
islet    O
cell    O
carcinomas    O
which    O
produce    O
excessive    O
insulin    O
.    O

Doxorubicin    O
and    O
streptozotocin    B-Calculation105802185
have    O
also    O
been    O
used    O
successfully    O
to    O
selectively    O
damage    O
alpha    O
cells    O
of    O
the    O
pancreatic    O
islets    O
.    O

However    O
,    O
T2D    O
in    O
model    O
organisms    O
are    O
introduced    O
via    O
surgery    O
of    O
partial/    O
whole    O
pancreas    O
,    O
or    O
using    O
chemicals    O
such    O
as    O
Streptozotocin    B-Calculation105802185
.    O

Streptozocin    B-Calculation105802185

The    O
primary    O
metabolites    O
are    O
amphetamine    O
and    O
4-hydroxymethamphetamine    O
;    O
other    O
minor    O
metabolites    O
include    O
:    O
,    O
,    O
,    O
benzoic    O
acid    O
,    O
hippuric    B-Calculation105802185
acid    I-Calculation105802185
,    O
norephedrine    O
,    O
and    O
phenylacetone    O
,    O
the    O
metabolites    O
of    O
amphetamine    O
.    O

S.    O
pyogenes    O
"    O
is    O
CAMP    O
and    O
hippurate    B-Calculation105802185
tests    O
negative    O
.    O

An    O
early    O
synthesis    O
by    O
Buck    O
and    O
co    O
-    O
workers    O
began    O
with    O
3,4-dimethoxybenzaldehyde    O
(    O
veratraldehyde    O
)    O
,    O
which    O
was    O
condensed    O
with    O
hippuric    B-Calculation105802185
acid    I-Calculation105802185
to    O
give    O
the    O
azlactone    O
;    O
this    O
was    O
hydrolyzed    O
with    O
NaOH    O
to    O
the    O
corresponding    O
pyruvic    O
acid    O
,    O
which    O
was    O
then    O
converted    O
to    O
its    O
oxime    O
;    O
treatment    O
of    O
the    O
oxime    O
with    O
acetic    O
anhydride    O
gave    O
3,4-dimethoxyphenylacetonitrile    O
,    O
which    O
was    O
catalytically    O
reduced    O
(    O
H2/Pd    O
)    O
in    O
the    O
presence    O
of    O
excess    O
dimethylamine    O
to    O
N    O
,    O
N    O
-    O
dimethyl-3,4-dimethoxyphenethylamine    O
;    O
finally    O
,    O
the    O
methoxy    O
-    O
groups    O
were    O
cleaved    O
with    O
HCl    O
to    O
give    O
DMDA    O
as    O
its    O
hydrochloride    O
salt    O
.    O

This    O
enzyme    O
plays    O
a    O
prominent    O
role    O
in    O
converting    O
benzoic    O
acid    O
(    O
benzoate    O
)    O
into    O
hippuric    B-Calculation105802185
acid    I-Calculation105802185
(    O
N    O
-    O
benzoylglycine    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
benzoyl    O
-    O
CoA    O
and    O
glycine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N-benzoylglycine    B-Calculation105802185
.    O

3-Iodotyrosine    B-Calculation105802185
•    O

The    O
chromosomal    O
background    O
of    O
EHA101    O
is    O
C58C1    O
,    O
a    O
cured    O
nopaline    B-Calculation105802185
strain    O
.    O

The    O
sequon    O
is    O
an    O
Asn    O
-    O
X    O
-    O
Ser    O
or    O
Asn    O
-    O
X    O
-    O
Thr    O
sequence    O
,    O
where    O
X    O
is    O
any    O
amino    O
acid    O
except    O
proline    O
and    O
the    O
glycan    O
may    O
be    O
composed    O
of    O
"    O
N    O
"-    O
acetylgalactosamine    O
,    O
galactose    O
,    O
neuraminic    B-Calculation105802185
acid    I-Calculation105802185
,    O
"    O
N    O
"-    O
acetylglucosamine    O
,    O
fucose    O
,    O
mannose    O
,    O
and    O
other    O
monosaccharides    O
.    O

Modification    O
reactions    O
may    O
involve    O
the    O
addition    O
of    O
a    O
phosphate    O
or    O
acetyl    O
group    O
onto    O
the    O
sugars    O
,    O
or    O
the    O
addition    O
of    O
new    O
sugars    O
,    O
such    O
as    O
neuraminic    B-Calculation105802185
acid    I-Calculation105802185
.    O

Viral    O
neuraminidase    O
cleaves    O
terminal    O
neuraminic    B-Calculation105802185
acid    I-Calculation105802185
(    O
also    O
called    O
sialic    O
acid    O
)    O
residues    O
from    O
glycan    O
structures    O
on    O
the    O
surface    O
of    O
the    O
infected    O
cell    O
.    O

mitobronitol    B-Calculation105802185
(    O
INN    O
)    O

It    O
is    O
a    O
structural    O
analogue    O
of    O
2-C-methyl-D-erythrose    B-Calculation105802185
4-phosphate    I-Calculation105802185
.    O

They    O
made    O
several    O
discoveries    O
critical    O
to    O
understanding    O
carbohydrate    O
metabolism    O
,    O
including    O
the    O
isolation    O
and    O
discovery    O
of    O
the    O
Cori    B-Calculation105802185
ester    I-Calculation105802185
,    O
glucose-1    O
phosphate    O
,    O
and    O
the    O
understanding    O
of    O
the    O
Cori    O
cycle    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
beta-D-glucose    B-Calculation105802185
1-phosphate    I-Calculation105802185
,    O
and    O
one    O
product    O
,    O
beta    O
-    O
D    O
-    O
glucose    O
6-phosphate    O
.    O

Galactose    O
is    O
therefore    O
preferentially    O
converted    O
into    O
glucose-1-phosphate    B-Calculation105802185
,    O
which    O
may    O
be    O
shunted    O
into    O
glycolysis    O
or    O
the    O
inositol    O
synthesis    O
pathway    O
.    O

The    O
enzyme    O
removes    O
1,4    O
glycosyl    O
residues    O
from    O
outer    O
branches    O
of    O
glycogen    O
and    O
adds    O
inorganic    O
phosphate    O
to    O
form    O
glucose-1-phosphate    B-Calculation105802185
.    O

They    O
include    O
allosteric    O
enzymes    O
that    O
catalyze    O
the    O
production    O
of    O
glucose-1-phosphate    B-Calculation105802185
from    O
a    O
glucan    O
such    O
as    O
glycogen    O
,    O
starch    O
or    O
maltodextrin    O
.    O

G6PD    O
converts    O
glucose-6-phosphate    B-Calculation105802185
into    O
6-phosphoglucono-δ-lactone    O
and    O
is    O
the    O
rate    O
-    O
limiting    O
enzyme    O
of    O
this    O
metabolic    O
pathway    O
that    O
supplies    O
reducing    O
energy    O
to    O
cells    O
by    O
maintaining    O
the    O
level    O
of    O
the    O
reduced    O
form    O
of    O
the    O
co    O
-    O
enzyme    O
nicotinamide    O
adenine    O
dinucleotide    O
phosphate    O
(    O
NADPH    O
)    O
.    O

More    O
precisely    O
,    O
it    O
facilitates    O
the    O
interconversion    O
of    O
glucose    B-Calculation105802185
1-phosphate    I-Calculation105802185
and    O
glucose    B-Calculation105802185
6-phosphate    I-Calculation105802185
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
D-glucose    B-Calculation105802185
6-phosphate    I-Calculation105802185
,    O
and    O
one    O
product    O
,    O
1D    O
-    O
myo    O
-    O
inositol    O
3-phosphate    O
.    O

The    O
glucose-1-phosphate    O
generated    O
in    O
step    O
3    O
of    O
the    O
Leloir    O
pathway    O
may    O
be    O
isomerized    O
to    O
glucose-6-phosphate    B-Calculation105802185
by    O
phosphoglucomutase    O
.    O

G6PD    B-Calculation105802185
reduces    O
NADP+    O
to    O
NADPH    O
while    O
oxidizing    O
glucose-6-phosphate    O
.    O

Reaction    O
1    O
is    O
a    O
pretreatment    O
of    O
the    O
sample    O
performed    O
by    O
adding    O
glucokinase    O
to    O
convert    O
glucose    O
to    O
glucose    B-Calculation105802185
6-phosphate    I-Calculation105802185
in    O
the    O
presence    O
of    O
adenosine    O
triphosphate    O
,    O
pyruvate    O
kinase    O
,    O
and    O
phosphoenol    O
pyruvate    O
.    O

G6Pase    O
is    O
located    O
in    O
the    O
endoplasmic    O
reticulum    O
(    O
ER    O
)    O
and    O
catalyzes    O
the    O
hydrolysis    O
of    O
glucose    B-Calculation105802185
6-phosphate    I-Calculation105802185
to    O
glucose    O
and    O
phosphate    O
in    O
the    O
last    O
step    O
of    O
the    O
gluconeogenic    O
and    O
glycogenolytic    O
pathways    O
.    O

The    O
glucose    O
that    O
enters    O
the    O
β-cell    O
is    O
phosphorylated    O
to    O
glucose-6-phosphate    B-Calculation105802185
(    O
G-6-P    O
)    O
by    O
glucokinase    O
(    O
hexokinase    O
IV    O
)    O
which    O
is    O
not    O
inhibited    O
by    O
G-6-P    O
in    O
the    O
way    O
that    O
the    O
hexokinases    O
in    O
other    O
tissues    O
(    O
hexokinase    O
I    O
–    O

The    O
heterotrophic    O
processing    O
of    O
carbohydrates    O
involves    O
isomerization    O
of    O
triose    O
phosphates    O
and    O
interconversion    O
between    O
fructose-6-phosphate    O
and    O
glucose-6-phosphate    B-Calculation105802185
.    O

It    O
is    O
produced    O
from    O
glucose-6-phosphate    B-Calculation105802185
by    O
glucose-6-phosphate    O
dehydrogenase    O
.    O

Volume    B-Calculation105802185
integral    I-Calculation105802185

Thus    O
,    O
the    O
total    O
heat    O
content    O
is    O
the    O
product    O
of    O
the    O
density    O
,    O
specific    O
heat    O
capacity    O
,    O
and    O
the    O
volume    B-Calculation105802185
integral    I-Calculation105802185
of    O
temperature    O
over    O
the    O
three    O
-    O
dimensional    O
region    O
of    O
the    O
ocean    O
in    O
question    O
.    O

Considering    O
the    O
statement    O
in    O
words    O
above    O
-    O
there    O
are    O
three    O
elements    O
to    O
the    O
theorem    O
,    O
which    O
involve    O
writing    O
energy    O
transfer    O
(    O
per    O
unit    O
time    O
)    O
as    O
volume    B-Calculation105802185
integral    I-Calculation105802185
:    O

The    O
spatial    O
volume    B-Calculation105802185
integral    I-Calculation105802185
of    O
the    O
Lagrangian    O
density    O
is    O
the    O
Lagrangian    O
,    O
in    O
3d    O

converges    O
absolutely    O
,    O
and    O
is    O
known    O
as    O
the    O
Euler    B-Calculation105802185
integral    I-Calculation105802185
of    I-Calculation105802185
the    I-Calculation105802185
second    I-Calculation105802185
kind    I-Calculation105802185
(    O
the    O
Euler    O
integral    O
of    O
the    O
first    O
kind    O
defines    O
the    O
beta    O
function    O
)    O
.    O

Calculate    B-Calculation105802185
Linux    I-Calculation105802185

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D-ribose    B-Calculation105802185
5-phosphate    I-Calculation105802185
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D    O
-    O
ribose    O
1,5-bisphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D    O
-    O
ribose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D-ribose    B-Calculation105802185
5-phosphate    I-Calculation105802185
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ADP    O
and    O
D-ribose    B-Calculation105802185
5-phosphate    I-Calculation105802185
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
ADP    O
-    O
ribose    O
.    O

Ribose    B-Calculation105802185
5-phosphate    I-Calculation105802185
is    O
both    O
a    O
product    O
and    O
an    O
intermediate    O
of    O
the    O
pentose    O
phosphate    O
pathway    O
.    O

If    O
"    O
f    O
"    O
is    O
an    O
"L"2-function    B-Calculation105802185
on    O
R    O
or    O
R"N    O
"    O
,    O
say    O
,    O
then    O
so    O
is    O
and    O
.    O

Pfeffer    O
gave    O
his    O
name    O
to    O
the    O
Pfeffer    O
integral    O
,    O
which    O
extends    O
a    O
Riemann-type    B-Calculation105802185
construction    I-Calculation105802185
for    O
the    O
integral    O
of    O
a    O
measurable    O
function    O
both    O
to    O
higher    O
-    O
dimensional    O
domains    O
and    O
,    O
in    O
the    O
case    O
of    O
one    O
dimension    O
,    O
to    O
a    O
superset    O
of    O
the    O
Lebesgue    B-Calculation105802185
integrable    I-Calculation105802185
functions    O
.    O

In    O
one    O
dimension    O
his    O
work    O
as    O
well    O
as    O
similarities    O
between    O
the    O
Pfeffer    O
integral    O
and    O
the    O
McShane    O
integral    O
indicate    O
that    O
the    O
integral    O
is    O
more    O
general    O
than    O
the    O
Lebesgue    B-Calculation105802185
integral    I-Calculation105802185
and    O
yet    O
less    O
general    O
than    O
the    O
Henstock    O
integral    O
.    O

Lebesgue    B-Calculation105802185
integration    I-Calculation105802185
–    O

It    O
is    O
not    O
an    O
integral    O
in    O
the    O
Lebesgue    B-Calculation105802185
sense    O
;    O
it    O
is    O
called    O
integration    O
because    O
it    O
has    O
analogous    O
properties    O
and    O
since    O
it    O
is    O
used    O
in    O
physics    O
as    O
a    O
sum    O
over    O
histories    O
for    O
fermions    O
,    O
an    O
extension    O
of    O
the    O
path    O
integral    O
.    O

In    O
all    O
cases    O
,    O
including    O
those    O
in    O
which    O
the    O
distribution    O
is    O
neither    O
discrete    O
nor    O
continuous    O
,    O
the    O
mean    O
is    O
the    O
Lebesgue    B-Calculation105802185
integral    I-Calculation105802185
of    O
the    O
random    O
variable    O
with    O
respect    O
to    O
its    O
probability    O
measure    O
.    O

where    O
the    O
imaginary    O
part    O
of    O
a    O
complex    O
number    O
is    O
given    O
by    O
.The    O
integral    O
may    O
be    O
not    O
Lebesgue-integrable    B-Calculation105802185
;    O
for    O
example    O
,    O
when    O
"    O
X    O
"    O
is    O
the    O
discrete    O
random    O
variable    O
that    O
is    O
always    O
0    O
,    O
it    O
becomes    O
the    O
Dirichlet    B-Calculation105802185
integral    I-Calculation105802185
.    O

It    O
serves    O
as    O
an    O
instructive    O
and    O
useful    O
precursor    O
of    O
the    O
Lebesgue    B-Calculation105802185
integral    I-Calculation105802185
,    O
and    O
an    O
invaluable    O
tool    O
in    O
unifying    O
equivalent    O
forms    O
of    O
statistical    O
theorems    O
that    O
apply    O
to    O
discrete    O
and    O
continuous    O
probability    O
.    O

An    O
important    O
generalization    O
is    O
the    O
Lebesgue    O
–    O
Stieltjes    O
integral    O
which    O
generalizes    O
the    O
Riemann    O
–    O
Stieltjes    O
integral    O
in    O
a    O
way    O
analogous    O
to    O
how    O
the    O
Lebesgue    B-Calculation105802185
integral    I-Calculation105802185
generalizes    O
the    O
Riemann    O
integral    O
.    O

This    O
notation    O
reminds    O
also    O
that    O
if    O
'    O
is    O
of    O
class    O
(    O
i.e.    O
a    O
continuous    O
and    O
differentiable    O
function    O
having    O
continuous    O
derivatives    O
)    O
then    O
its    O
variation    O
is    O
exactly    O
the    O
integral    B-Calculation105802185
of    O
the    O
absolute    O
value    O
of    O
its    O
gradient    O
.    O

Part    O
I    O
of    O
the    O
theorem    O
then    O
says    O
:    O
if    O
"    O
f    O
"    O
is    O
any    O
Lebesgue    B-Calculation105802185
integrable    I-Calculation105802185
function    O
on    O
and    O
"    O
x"0    O
is    O
a    O
number    O
in    O
such    O
that    O
"    O
f    O
"    O
is    O
continuous    O
at    O
"    O
x"0    O
,    O
then    O

Shortcomings    O
of    O
Riemann    O
's    O
dependence    O
on    O
intervals    O
and    O
continuity    O
motivated    O
newer    O
definitions    O
,    O
especially    O
the    O
Lebesgue    B-Calculation105802185
integral    I-Calculation105802185
,    O
which    O
is    O
founded    O
on    O
an    O
ability    O
to    O
extend    O
the    O
idea    O
of    O
"    O
measure    O
"    O
in    O
much    O
more    O
flexible    O
ways    O
.    O

The    O
Lebesgue    O
–    O
Stieltjes    O
integral    O
,    O
further    O
developed    O
by    O
Johann    O
Radon    O
,    O
which    O
generalizes    O
the    O
Riemann–Stieltjes    B-Calculation105802185
and    O
Lebesgue    B-Calculation105802185
integrals    I-Calculation105802185
.    O

The    O
Daniell    B-Calculation105802185
integral    I-Calculation105802185
,    O
which    O
subsumes    O
the    O
Lebesgue    B-Calculation105802185
integral    I-Calculation105802185
and    O
Lebesgue    O
–    O
Stieltjes    O
integral    O
without    O
the    O
dependence    O
on    O
measures    O
.    O

Summations    O
and    O
integrals    O
can    O
be    O
put    O
on    O
the    O
same    O
foundations    O
using    O
the    O
theory    O
of    O
Lebesgue    B-Calculation105802185
integral    I-Calculation105802185
or    O
time    O
scale    O
calculus    O
.    O

Lebesgue    B-Calculation105802185
integration    I-Calculation105802185

In    O
its    O
most    O
general    O
form    O
,    O
the    O
ambit    O
field    O
,    O
,    O
is    O
defined    O
by    O
a    O
constant    O
plus    O
a    O
stochastic    O
integral    O
,    O
where    O
the    O
integration    O
is    O
done    O
with    O
respect    O
to    O
a    O
"    O
Lévy    O
basis    O
"    O
,    O
plus    O
a    O
smooth    O
term    O
given    O
by    O
an    O
ordinary    O
Lebesgue    B-Calculation105802185
integral    I-Calculation105802185
.    O

In    O
strip    O
151    O
the    O
rats    O
educate    O
themselves    O
and    O
quote    O
several    O
famous    O
authors    O
and    O
scientists    O
,    O
including    O
Aristotle    O
,    O
"    O
Hamlet    O
"    O
's    O
"    O
To    O
be    O
or    O
not    O
to    O
be    O
"    O
speech    O
,    O
the    O
Lebesgue    B-Calculation105802185
integration    I-Calculation105802185
,    O
Ivan    O
Pavlov    O
's    O
test    O
and    O
the    O
quote    O
"    O
The    O
strongest    O
are    O
most    O
powerful    O
when    O
they    O
are    O
alone    O
"    O
from    O
Friedrich    O
Schiller    O
's    O
play    O
"    O
William    O
Tell    O
"    O
.    O

An    O
absolutely    O
integrable    O
function    O
is    O
a    O
function    O
whose    O
absolute    O
value    O
is    O
integrable    B-Calculation105802185
,    O
meaning    O
that    O
the    O
integral    O
of    O
the    O
absolute    O
value    O
over    O
the    O
whole    O
domain    O
is    O
finite    O
.    O

In    O
Lebesgue    B-Calculation105802185
integration    I-Calculation105802185
,    O
this    O
is    O
exactly    O
the    O
requirement    O
for    O
"    O
f    O
"    O
itself    O
to    O
be    O
considered    O
integrable    O
(    O
with    O
the    O
integral    O
then    O
equaling    O
)    O
,    O
so    O
that    O
in    O
fact    O
"    O
absolutely    O
integrable    O
"    O
means    O
the    O
same    O
thing    O
as    O
"    O
Lebesgue    O
integrable    O
"    O
.    O

Chloralose    B-Calculation105802185
(    O
a    O
narcotic    O
prodrug    O
)    O

:    O
D11AX09    O
Oxaceprol    B-Calculation105802185

:    O
is    O
the    O
exponential    B-Calculation105802185
integral    I-Calculation105802185
,    O
a    O
transcendent    O
mathematical    O
function    O

The    O
first    O
term    O
li("x    O
"    O
)    O
is    O
the    O
usual    O
logarithmic    B-Calculation105802185
integral    I-Calculation105802185
function    I-Calculation105802185
;    O
the    O
expression    O
li("x""ρ    O
"    O
)    O
in    O
the    O
second    O
term    O
should    O
be    O
considered    O
as    O
Ei(ρ    O
ln    O
"    O
x    O
"    O
)    O
,    O
where    O
Ei    O
is    O
the    O
analytic    O
continuation    O
of    O
the    O
exponential    B-Calculation105802185
integral    I-Calculation105802185
function    O
from    O
negative    O
reals    O
to    O
the    O
complex    O
plane    O
with    O
branch    O
cut    O
along    O
the    O
positive    O
reals    O
.    O

where    O
Ei    O
is    O
the    O
exponential    B-Calculation105802185
integral    I-Calculation105802185
and    O
"    O
ξ    O
"    O
is    O
the    O
positive    O
root    O
of    O

where    O
Ein("z    O
"    O
)    O
is    O
the    O
entire    O
exponential    B-Calculation105802185
integral    I-Calculation105802185
.    O

Exponential    B-Calculation105802185
integral    I-Calculation105802185
,    O
a    O
special    O
function    O
defined    O
on    O
the    O
complex    O
plane    O
given    O
the    O
symbol    O
Ei    O

In    O
particular    O
,    O
the    O
quantile    O
is    O
1.96    B-Calculation105802185
;    O
therefore    O
a    O
normal    O
random    O
variable    O
will    O
lie    O
outside    O
the    O
interval    O
in    O
only    O
5%    O
of    O
cases    O
.    O

Some    O
anticonvulsants    O
including    O
:    O
carbamazepine    O
,    O
ethosuximide    O
,    O
phenytoin    O
,    O
topiramate    B-Calculation105802185
,    O
valproate    O
.    O

:*    O
topiramate    B-Calculation105802185

Topiramate    B-Calculation105802185
,    O
GABA    O
-    O
receptor    O
related    O
anticonvulsant    O
and    O
mood    O
-    O
stabilizer    O

Some    O
new    O
antiepileptic    O
drugs    O
such    O
as    O
topiramate    B-Calculation105802185
,    O
gabapentin    O
,    O
and    O
lamotrigine    O
have    O
already    O
been    O
developed    O
and    O
have    O
shown    O
promise    O
in    O
treatment    O
of    O
PTE    O
.    O

Cimetidine    O
,    O
omeprazole    O
,    O
oxcarbazepine    O
,    O
ticlopidine    O
,    O
topiramate    B-Calculation105802185
,    O
ketoconazole    O
,    O
itraconazole    O
,    O
disulfiram    O
,    O
fluvoxamine    O
,    O
isoniazid    O
,    O
erythromycin    O
,    O
probenecid    O
,    O
propranolol    O
,    O
imipramine    O
,    O
ciprofloxacin    O
,    O
fluoxetine    O
,    O
and    O
valproic    O
acid    O
prolong    O
the    O
action    O
of    O
diazepam    O
by    O
inhibiting    O
its    O
elimination    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    B-Calculation105802185
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

Topiramate    B-Calculation105802185
,    O
an    O
anti    O
-    O
epileptic    O
drug    O
,    O
has    O
been    O
used    O
to    O
treat    O
excoriation    O
disorder    O
;    O
in    O
a    O
small    O
study    O
of    O
individuals    O
with    O
Prader–    O

Zonisamide    O
has    O
been    O
studied    O
for    O
and    O
used    O
as    O
a    O
migraine    O
preventative    O
medication    O
,    O
when    O
topiramate    B-Calculation105802185
is    O
either    O
ineffective    O
or    O
can    O
not    O
be    O
continued    O
due    O
to    O
side    O
effects    O
.    O

Zonisamide    O
and    O
other    O
carbonic    O
anhydrase    O
inhibitors    O
such    O
as    O
topiramate    B-Calculation105802185
,    O
furosemide    O
,    O
and    O
hydrochlorothiazide    O
have    O
been    O
known    O
to    O
interfere    O
with    O
amobarbital    O
,    O
which    O
has    O
led    O
to    O
inadequate    O
anesthetization    O
during    O
the    O
Wada    O
test    O
.    O

Though    O
antiepileptic    O
drugs    O
(    O
membrane    O
-    O
stabilizing    O
drugs    O
)    O
such    O
as    O
pregabalin    O
,    O
gabapentin    O
,    O
topiramate    B-Calculation105802185
,    O
and    O
lamotrigine    O
improve    O
symptoms    O
,    O
there    O
is    O
no    O
effective    O
permanent    O
or    O
long    O
-    O
term    O
treatment    O
for    O
SUNCT    O
.    O

An    O
anticonvulsant    O
called    O
topiramate    B-Calculation105802185
has    O
helped    O
patients    O
in    O
three    O
cases    O
and    O
may    O
be    O
a    O
viable    O
treatment    O
for    O
the    O
future    O
.    O

Controlled    O
clinical    O
trials    O
of    O
gabapentin    O
yielded    O
mixed    O
results    O
in    O
efficacy    O
against    O
essential    O
tremor    O
while    O
topiramate    B-Calculation105802185
was    O
shown    O
to    O
be    O
effective    O
in    O
a    O
larger    O
double    O
-    O
blind    O
controlled    O
study    O
,    O
resulting    O
in    O
both    O
lower    O
Fahn    O
-    O
Tolosa    O
-    O
Marin    O
tremor    O
scale    O
ratings    O
and    O
better    O
function    O
and    O
disability    O
as    O
compared    O
to    O
placebo    O
.    O

milacemide    B-Calculation105802185
(    O
INN    O
)    O

Haldane    O
required    O
a    O
number    O
of    O
conditions    O
for    O
this    O
relationship    O
to    O
hold    O
including    O
the    O
existence    O
of    O
an    O
Edgeworth    B-Calculation105802185
expansion    I-Calculation105802185
and    O
the    O
uniqueness    O
of    O
both    O
the    O
median    O
and    O
the    O
mode    O
.    O

probability    O
,    O
such    O
as    O
the    O
Edgeworth    B-Calculation105802185
series    I-Calculation105802185
;    O

"    O
The    O
early    O
history    O
of    O
the    O
cumulants    O
and    O
the    O
Gram–Charlier    B-Calculation105802185
series    I-Calculation105802185
"    O
"    O
International    O
Statistical    O
Review    O
"    O
volume    O
68    O
(    O
2000    O
)    O
,    O
number    O
2    O
,    O
´    O
:    O
137–153    O
.    O

Ututo    B-Calculation105802185

The    O
most    O
straightforward    O
higher    O
dimension    O
analogues    O
of    O
these    O
are    O
the    O
Riesz    B-Calculation105802185
transform    I-Calculation105802185
,    O
which    O
replace    O
"    O
K"("x    O
"    O
)    O
=    O
1/"x    O
"    O
with    O

"N"-Formylmethionine    B-Calculation105802185

IF2    O
binds    O
to    O
an    O
initiator    B-Calculation105802185
tRNA    I-Calculation105802185
and    O
controls    O
the    O
entry    O
of    O
tRNA    O
onto    O
the    O
ribosome    O
.    O

It    O
binds    O
to    O
the    O
small    O
16S    O
rRNA    O
of    O
the    O
30S    O
subunit    O
of    O
the    O
bacterial    O
ribosome    O
,    O
interfering    O
with    O
the    O
binding    O
of    O
formyl-methionyl-tRNA    B-Calculation105802185
to    O
the    O
30S    O
subunit    O
.    O

These    O
receptors    O
were    O
originally    O
identified    O
by    O
their    O
ability    O
to    O
bind    O
N    O
-    O
formyl    O
peptides    O
such    O
as    O
"N"-formylmethionine    B-Calculation105802185
produced    O
by    O
the    O
degradation    O
of    O
either    O
bacterial    O
or    O
host    O
cells    O
.    O

Studies    O
conducted    O
in    O
the    O
1970s    O
found    O
that    O
a    O
series    O
of    O
N-Formylmethionine    B-Calculation105802185
-    O
containing    O
oligopeptides    O
,    O
including    O
the    O
most    O
potent    O
and    O
best    O
known    O
member    O
of    O
this    O
series    O
,    O
N    O
-    O
formyl    O
-    O
methionyl    O
-    O
leucyl    O
-    O
phenylalanine    O
(    O
FMLP    O
or    O
fMet    O
-    O
Leu    O
-    O
Phe    O
)    O
,    O
stimulated    O
rabbit    O
and    O
human    O
neutrophils    O
by    O
an    O
apparent    O
receptor    O
-    O
dependent    O
mechanism    O
to    O
migrate    O
in    O
a    O
directional    O
pattern    O
in    O
classical    O
laboratory    O
assays    O
of    O
chemotaxis    O
.    O

Examples    O
of    O
EAARIs    O
include    O
dihydrokainic    O
acid    O
(    O
DHK    O
)    O
and    O
WAY-213,613    B-Calculation105802185
,    O
selective    O
blockers    O
of    O
EAAT2    O
(    O
GLT-1    O
)    O
,    O
and    O
L-"trans"-2,4-PDC    O
,    O
a    O
non    O
-    O
selective    O
blocker    O
of    O
all    O
five    O
EAATs    O
.    O

Streptomyces    O
alanosinicus    O
"    O
produces    O
the    O
antibiotics    O
alanosine    B-Calculation105802185
and    O
spicamycin    O
.    O

In    O
theory    O
of    O
vibrations    O
,    O
Duhamel's    B-Calculation105802185
integral    I-Calculation105802185
is    O
a    O
way    O
of    O
calculating    O
the    O
response    O
of    O
linear    O
systems    O
and    O
structures    O
to    O
arbitrary    O
time    O
-    O
varying    O
external    O
perturbation    O
.    O

where    O
li    O
is    O
the    O
logarithmic    B-Calculation105802185
integral    I-Calculation105802185
function    O
.    O

The    O
first    O
term    O
li("x    O
"    O
)    O
is    O
the    O
usual    O
logarithmic    B-Calculation105802185
integral    I-Calculation105802185
function    I-Calculation105802185
;    O
the    O
expression    O
li("x""ρ    O
"    O
)    O
in    O
the    O
second    O
term    O
should    O
be    O
considered    O
as    O
Ei(ρ    O
ln    O
"    O
x    O
"    O
)    O
,    O
where    O
Ei    O
is    O
the    O
analytic    O
continuation    O
of    O
the    O
exponential    B-Calculation105802185
integral    I-Calculation105802185
function    O
from    O
negative    O
reals    O
to    O
the    O
complex    O
plane    O
with    O
branch    O
cut    O
along    O
the    O
positive    O
reals    O
.    O

where    O
is    O
the    O
integral    B-Calculation105802185
logarithm    I-Calculation105802185
and    O
is    O
the    O
binomial    O
coefficient    O
.    O

Data    O
gathered    O
by    O
Gauss    O
and    O
Goldschmidt    O
on    O
the    O
growth    O
of    O
the    O
logarithmic    B-Calculation105802185
integral    I-Calculation105802185
compared    O
to    O
the    O
distribution    O
of    O
prime    O
numbers    O
was    O
cited    O
by    O
Riemann    O
in    O
"    O
On    O
the    O
Number    O
of    O
Primes    O
Less    O
Than    O
a    O
Given    O
Magnitude    O
"    O
,    O
Riemann    O
's    O
seminal    O
paper    O
on    O
the    O
prime    O
-    O
counting    O
function    O
.    O

He    O
also    O
published    O
on    O
the    O
logarithmic    B-Calculation105802185
integral    I-Calculation105802185
function    I-Calculation105802185
.    O

In    O
mathematics    O
,    O
and    O
more    O
precisely    O
in    O
analysis    O
,    O
the    O
Wallis    B-Calculation105802185
integrals    I-Calculation105802185
constitute    O
a    O
family    O
of    O
integrals    O
introduced    O
by    O
John    O
Wallis    O
.    O

The    O
Daniell    B-Calculation105802185
integral    I-Calculation105802185
,    O
which    O
subsumes    O
the    O
Lebesgue    B-Calculation105802185
integral    I-Calculation105802185
and    O
Lebesgue    O
–    O
Stieltjes    O
integral    O
without    O
the    O
dependence    O
on    O
measures    O
.    O

This    O
is    O
the    O
approach    O
of    O
Daniell    B-Calculation105802185
for    O
the    O
case    O
of    O
real    O
-    O
valued    O
functions    O
on    O
a    O
set    O
,    O
generalized    O
by    O
Nicolas    O
Bourbaki    O
to    O
functions    O
with    O
values    O
in    O
a    O
locally    O
compact    O
topological    O
vector    O
space    O
.    O

Brivanib    B-Calculation105802185
alaninate    I-Calculation105802185
(    O
BMS-582664    O
)    O
—    O
development    O
terminated    O

The    O
formula    O
is    O
derived    O
by    O
computing    O
the    O
double    B-Calculation105802185
integral    I-Calculation105802185
in    O
polar    O
coordinates    O
.    O

In    O
mathematics    O
,    O
Hadjicostas    O
's    O
formula    O
is    O
a    O
formula    O
relating    O
a    O
certain    O
double    B-Calculation105802185
integral    I-Calculation105802185
to    O
values    O
of    O
the    O
Gamma    O
function    O
and    O
the    O
Riemann    O
zeta    O
function    O
.    O

This    O
double    B-Calculation105802185
integral    I-Calculation105802185
can    O
be    O
defined    O
using    O
Riemann    O
sums    O
,    O
and    O
represents    O
the    O
(    O
signed    O
)    O
volume    O
under    O
the    O
graph    O
of    O
over    O
the    O
domain    O
"    O
R    O
"    O
.    O

A    O
"    O
surface    O
integral    O
"    O
is    O
a    O
definite    O
integral    O
taken    O
over    O
a    O
surface    O
(    O
which    O
may    O
be    O
a    O
curved    O
set    O
in    O
space    O
)    O
;    O
it    O
can    O
be    O
thought    O
of    O
as    O
the    O
double    B-Calculation105802185
integral    I-Calculation105802185
analog    O
of    O
the    O
line    B-Calculation105802185
integral    I-Calculation105802185
.    O

Multiple    B-Calculation105802185
integral    I-Calculation105802185

In    O
mathematics    O
,    O
a    O
surface    O
integral    O
is    O
a    O
generalization    O
of    O
multiple    B-Calculation105802185
integral    I-Calculation105802185
to    O
integration    O
over    O
surfaces    O
.    O

It    O
can    O
be    O
thought    O
of    O
as    O
the    O
double    B-Calculation105802185
integral    I-Calculation105802185
analog    O
of    O
the    O
line    B-Calculation105802185
integral    I-Calculation105802185
.    O

Two    O
units    O
can    O
combine    O
to    O
form    O
3,3'-diiodothyronine    B-Calculation105802185
.    O

In    O
mathematics    O
,    O
a    O
nonelementary    B-Calculation105802185
antiderivative    I-Calculation105802185
of    O
a    O
given    O
elementary    O
function    O
is    O
an    O
antiderivative    O
that    O
is    O
,    O
itself    O
,    O
not    O
an    O
"    O
elementary    O
function    O
"    O
(    O
i.e.    O
a    O
function    O
constructed    O
from    O
a    O
finite    O
number    O
of    O
quotients    O
of    O
constant    O
,    O
algebraic    O
,    O
exponential    O
,    O
and    O
logarithmic    O
functions    O
using    O
field    O
operations    O
)    O
.    O

Many    O
nonelementary    B-Calculation105802185
integral    I-Calculation105802185
can    O
be    O
expanded    O
in    O
a    O
Taylor    O
series    O
and    O
integrated    O
term    O
by    O
term    O
.    O

Coffee    B-Calculation105802185
tea    I-Calculation105802185
leaves    I-Calculation105802185

Geometric    B-Calculation105802185
integral    I-Calculation105802185
;    O
several    O
related    O
multiplicative    O
analogues    O
to    O
classical    O
integration    O
.    O

Product    B-Calculation105802185
integral    I-Calculation105802185

Imprecise    B-Calculation105802185
probability    I-Calculation105802185

Levi    O
is    O
known    O
for    O
his    O
work    O
in    O
belief    O
revision    O
and    O
imprecise    B-Calculation105802185
probability    I-Calculation105802185
.    O

Imprecise    B-Calculation105802185
probability    I-Calculation105802185

The    O
more    O
basic    O
of    O
these    O
include    O
the    O
method    O
of    O
matched    O
asymptotic    O
expansions    O
and    O
WKB    B-Calculation105802185
approximation    I-Calculation105802185
for    O
spatial    O
problems    O
,    O
and    O
in    O
time    O
,    O
the    O
Poincaré    O
-    O
Lindstedt    O
method    O
,    O
the    O
method    O
of    O
multiple    O
scales    O
and    O
periodic    O
averaging    O
.    O

WKB    B-Calculation105802185
approximation    I-Calculation105802185

Using    O
the    O
WKB    B-Calculation105802185
approximation    I-Calculation105802185
,    O
the    O
tunneling    O
rate    O
can    O
be    O
determined    O
to    O
be    O
of    O
the    O
form    O

WKB    B-Calculation105802185
approximation    I-Calculation105802185
)    O
.    O

WKB    B-Calculation105802185
approximation    I-Calculation105802185

Wentzel–Kramers–Brillouin    B-Calculation105802185
approximation    I-Calculation105802185

It    O
appeared    O
originally    O
in    O
the    O
study    O
of    O
the    O
WKB    B-Calculation105802185
approximation    I-Calculation105802185
and    O
appears    O
frequently    O
in    O
the    O
study    O
of    O
quantization    O
,    O
quantum    O
chaos    O
trace    O
formulas    O
,    O
and    O
in    O
symplectic    O
geometry    O
and    O
topology    O
.    O

In    O
particular    O
,    O
in    O
the    O
Born–Oppenheimer    B-Calculation105802185
and    O
harmonic    O
approximations    O
,    O
i.e.    O
when    O
the    O
molecular    O
Hamiltonian    O
corresponding    O
to    O
the    O
electronic    O
ground    O
state    O
can    O
be    O
approximated    O
by    O
a    O
harmonic    O
oscillator    O
in    O
the    O
neighborhood    O
of    O
the    O
equilibrium    O
molecular    O
geometry    O
,    O
the    O
resonant    O
frequencies    O
are    O
associated    O
with    O
the    O
normal    O
modes    O
corresponding    O
to    O
the    O
molecular    O
electronic    O
ground    O
state    O
potential    O
energy    O
surface    O
.    O

Riazuddin    O
carefully    O
studied    O
American    O
theoretical    O
physicist    O
J.    O
Robert    O
Oppenheimer    O
's    O
approach    O
to    O
develop    O
the    O
first    O
implosion    O
device    O
,    O
and    O
made    O
further    O
advances    O
on    O
Tolman    O
-    O
Oppenheimer    O
-    O
Volkoff    O
limit    O
,    O
Oppenheimer    O
-    O
Phillips    O
process    O
,    O
Born–Oppenheimer    B-Calculation105802185
approximation    I-Calculation105802185
.    O

Almost    O
all    O
calculations    O
of    O
molecular    O
wavefunctions    O
are    O
based    O
on    O
the    O
separation    O
of    O
the    O
Coulomb    O
Hamiltonian    O
first    O
devised    O
by    O
Born    B-Calculation105802185
and    I-Calculation105802185
Oppenheimer    I-Calculation105802185
.    O

the    O
neighboring    O
potential    O
energy    O
surfaces    O
are    O
needed    O
,    O
see    O
this    O
article    B-Calculation105802185
for    O
more    O
details    O
on    O
this    O
.    O

problem    O
is    O
solved    O
with    O
the    O
clamped    O
nucleus    O
Hamiltonian    O
arising    O
in    O
the    O
first    O
step    O
of    O
the    O
Born–Oppenheimer    B-Calculation105802185
approximation    I-Calculation105802185
.    O

As    O
explained    O
in    O
the    O
article    O
on    O
the    O
Born–Oppenheimer    B-Calculation105802185
approximation    I-Calculation105802185
,    O
a    O
sufficient    O
number    O
of    O
solutions    O

Born–Oppenheimer    B-Calculation105802185
approximation    I-Calculation105802185

The    O
tryptophan    B-Calculation105802185
tryptophylquinone    I-Calculation105802185
(    O
TTQ    O
)    O
group    O
of    O
MADH    O
then    O
donates    O
electrons    O
to    O
the    O
copper    O
center    O
of    O
amicyanin    O
,    O
which    O
in    O
turn    O
gives    O
the    O
electrons    O
to    O
the    O
heme    O
of    O
the    O
cytochrome    O
c.    O
In    O
"    O
P.    O
denitrificans    O
"    O
,    O
amicyanin    O
is    O
absolutely    O
required    O
for    O
electron    O
transfer    O
from    O
MADH    O
to    O
c    O
-    O
type    O
cytochromes    O
.    O

Pi    B-Calculation105802185
calculated    I-Calculation105802185
as    I-Calculation105802185
:    O
The    O
ancient    O
Egyptians    O
,    O
Babylonians    O
,    O
Indians    O
,    O
and    O
Greeks    O
had    O
long    O
made    O
approximations    O
for    O
π    O
by    O
the    O
time    O
the    O
Chinese    O
mathematician    O
and    O
astronomer    O
Liu    O
Xin    O
(    O
c.    O
46    O
BC–23    O
AD    O
)    O
improved    O
the    O
old    O
Chinese    O
approximation    O
of    O
simply    O
3    O
as    O
π    O
to    O
3.1547    O
as    O
π    O
(    O
with    O
evidence    O
on    O
vessels    O
dating    O
to    O
the    O
Wang    O
Mang    O
reign    O
period    O
,    O
9–23    O
AD    O
,    O
of    O
other    O
approximations    O
of    O
3.1590    O
,    O
3.1497    O
,    O
and    O
3.1679    O
)    O
.    O

In    O
mathematics    O
,    O
Machin    O
-    O
like    O
formulae    O
are    O
a    O
popular    O
technique    O
for    O
computing    O
π    O
to    O
a    O
large    B-Calculation105802185
number    I-Calculation105802185
of    I-Calculation105802185
digits    I-Calculation105802185
.    O

For    O
more    O
detailed    O
explanations    O
for    O
some    O
of    O
these    O
calculations    O
,    O
see    O
Approximations    B-Calculation105802185
of    I-Calculation105802185
.    O

History    B-Calculation105802185
of    I-Calculation105802185
numerical    I-Calculation105802185
approximations    I-Calculation105802185
of    I-Calculation105802185
π    I-Calculation105802185

In    O
Proposition    O
II    O
,    O
Archimedes    O
gives    O
an    O
approximation    B-Calculation105802185
of    O
the    O
value    O
of    O
pi    O
,    O
showing    O
that    O
it    O
is    O
greater    O
than    O
and    O
less    O
than    O
.    O

4-(γ-Glutamylamino)butanoic    B-Calculation105802185
acid    I-Calculation105802185
is    O
molecule    O
that    O
consists    O
of    O
L    O
-    O
glutamate    O
conjugated    O
to    O
γ-aminobutyric    O
acid    O
(    O
GABA    O
)    O
.    O

The    O
bifunctional    O
6-phosphofructo-2-kinase    O
/    O
fructose-2,6-bisphosphatase    O
(    O
PFKFB    O
)    O
regulates    O
the    O
steady    O
-    O
state    O
concentration    O
of    O
fructose    B-Calculation105802185
2,6-bisphosphate    I-Calculation105802185
,    O
an    O
activator    O
of    O
a    O
key    O
regulatory    O
enzyme    O
of    O
glycolysis    O
,    O
phosphofructokinase    O
.    O

Phosphofructokinase    O
is    O
an    O
important    O
control    O
point    O
in    O
the    O
glycolytic    O
pathway    O
,    O
since    O
it    O
is    O
one    O
of    O
the    O
irreversible    O
steps    O
and    O
has    O
key    O
allosteric    O
effectors    O
,    O
AMP    O
and    O
fructose    B-Calculation105802185
2,6-bisphosphate    I-Calculation105802185
(    O
F2,6BP    O
)    O
.    O

Fructose    B-Calculation105802185
2,6-bisphosphate    I-Calculation105802185
(    O
F2,6BP    O
)    O
is    O
a    O
very    O
potent    O
activator    O
of    O
phosphofructokinase    O
(    O
PFK-1    O
)    O
that    O
is    O
synthesized    O
when    O
F6P    O
is    O
phosphorylated    O
by    O
a    O
second    O
phosphofructokinase    O
(    O
PFK2    O
)    O
.    O

Riemann–Stieltjes    B-Calculation105802185
integral    I-Calculation105802185

Some    O
common    O
interpretations    O
of    O
"    O
dx    O
"    O
include    O
:    O
an    O
integrator    O
function    O
in    O
Riemann-Stieltjes    B-Calculation105802185
integration    I-Calculation105802185
(    O
indicated    O
by    O
"    O
dα"("x    O
"    O
)    O
in    O
general    O
)    O
,    O
a    O
measure    O
in    O
Lebesgue    O
theory    O
(    O
indicated    O
by    O
"    O
dμ    O
"    O
in    O
general    O
)    O
,    O
or    O
a    O
differential    O
form    O
in    O
exterior    O
calculus    O
(    O
indicated    O
by    O
in    O
general    O
)    O
.    O

The    O
Riemann–Stieltjes    B-Calculation105802185
integral    I-Calculation105802185
,    O
an    O
extension    O
of    O
the    O
Riemann    O
integral    O
.    O

The    O
Lebesgue    O
–    O
Stieltjes    O
integral    O
,    O
further    O
developed    O
by    O
Johann    O
Radon    O
,    O
which    O
generalizes    O
the    O
Riemann–Stieltjes    B-Calculation105802185
and    O
Lebesgue    B-Calculation105802185
integrals    I-Calculation105802185
.    O

The    O
Young    B-Calculation105802185
integral    I-Calculation105802185
,    O
which    O
is    O
a    O
kind    O
of    O
Riemann    O
–    O
Stieltjes    O
integral    O
with    O
respect    O
to    O
certain    O
functions    O
of    O
unbounded    O
variation    O
.    O

Riemann–Stieltjes    B-Calculation105802185
integral    I-Calculation105802185

Wilson    B-Calculation105802185
score    I-Calculation105802185
interval    I-Calculation105802185

Binomial    B-Calculation105802185
proportion    I-Calculation105802185
confidence    I-Calculation105802185
interval    I-Calculation105802185

Carbocisteine    B-Calculation105802185
(    O
INN    O
)    O
,    O
also    O
called    O
carbocysteine    B-Calculation105802185
(    O
USAN    O
)    O
,    O
is    O
a    O
mucolytic    O
that    O
reduces    O
the    O
viscosity    O
of    O
sputum    O
and    O
so    O
can    O
be    O
used    O
to    O
help    O
relieve    O
the    O
symptoms    O
of    O
chronic    O
obstructive    O
pulmonary    O
disorder    O
(    O
COPD    O
)    O
and    O
bronchiectasis    O
by    O
allowing    O
the    O
sufferer    O
to    O
bring    O
up    O
sputum    O
more    O
easily    O
.    O

After    O
ingestion    O
,    O
fructose    O
is    O
converted    O
to    O
fructose-1-phosphate    B-Calculation105802185
in    O
the    O
liver    O
by    O
fructokinase    O
.    O
Deficiencies    O
of    O
fructokinase    O
cause    O
essential    O
fructosuria    O
,    O
a    O
clinically    O
benign    O
condition    O
characterized    O
by    O
the    O
excretion    O
of    O
unmetabolized    O
fructose    O
in    O
the    O
urine    O
.    O

Aldolase    O
can    O
also    O
produce    O
DHAP    O
from    O
other    O
(    O
3S,4R)-ketose    O
1-phosphates    O
such    O
as    O
fructose    B-Calculation105802185
1-phosphate    I-Calculation105802185
and    O
sedoheptulose    O
1,7-bisphosphate    O
.    O

the    O
Gelfand–Pettis    B-Calculation105802185
integral    I-Calculation105802185
;    O

Levothyroxine    B-Calculation105802185
,    O
also    O
known    O
as    O
-thyroxine    B-Calculation105802185
,    O
is    O
a    O
manufactured    O
form    O
of    O
the    O
thyroid    O
hormone    O
,    O
thyroxine    O
(    O
T4    O
)    O
.    O

The    O
generic    O
name    O
is    O
levothyroxine    B-Calculation105802185
,    O
and    O
several    O
brands    O
are    O
available    O
.    O

Levothyroxine    B-Calculation105802185
,    O
by    O
the    O
trade    O
name    O
"    O
Letter    O
"    O

Physicians    O
are    O
cautioned    O
to    O
avoid    O
switching    O
patients    O
from    O
branded    O
to    O
generic    O
,    O
or    O
between    O
different    O
generic    O
manufacturers    O
,    O
when    O
prescriping    O
anti    O
-    O
epileptic    O
drugs    O
,    O
warfarin    O
,    O
and    O
levothyroxine    B-Calculation105802185
.    O

After    O
the    O
removal    O
of    O
a    O
thyroid    O
,    O
patients    O
usually    O
take    O
a    O
prescribed    O
oral    O
synthetic    O
thyroid    O
hormone    O
—    O
levothyroxine    B-Calculation105802185
(    O
Synthroid)—to    O
prevent    O
hypothyroidism    O
.    O

Women    O
with    O
symptoms    O
or    O
a    O
very    O
high    O
TSH    O
level    O
,    O
or    O
both    O
,    O
are    O
usually    O
prescribed    O
a    O
course    O
of    O
levothyroxine    B-Calculation105802185
.    O

Animals    O
resistant    O
to    O
weight    O
loss    O
,    O
despite    O
diet    O
and    O
exercise    O
changes    O
,    O
can    O
be    O
placed    O
on    O
levothyroxine    B-Calculation105802185
to    O
increase    O
metabolism    O
.    O

Levothyroxine    B-Calculation105802185

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
16-hydroxytabersonine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
16-methoxytabersonine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
5,8,13,13a    O
-    O
tetrahydrocolumbamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tetrahydropalmatine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
7-methylxanthine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
3,7-dimethylxanthine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
dimethyl    O
sulfide    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
trimethylsulfonium    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
thiol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
thioether    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
gamma    O
-    O
tocopherol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
alpha    O
-    O
tocopherol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
trans    O
-    O
aconitate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
(    O
E)-3-(methoxycarbonyl)pent-2-enedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
trans    O
-    O
aconitate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
(    O
E)-2-(methoxycarbonylmethyl)butenedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tRNA    O
containing    O
5-methylaminomethyl-2-thiouridylic    O
acid    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tRNA    O
containing    O
N1-methyladenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tRNA    O
containing    O
N6-methyladenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tRNA    O
containing    O
5-methylcytosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tRNA    O
containing    O
N1-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tRNA    O
containing    O
N2-Methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tRNA    O
containing    O
N7-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tRNA    O
containing    O
2'-O    O
-    O
methylguanosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
containing    O
uridine    O
at    O
position    O
54    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
tRNA    O
containing    O
ribothymidine    O
at    O
position    O
54    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
L    O
-    O
tryptophan    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
L-2-methyltryptophan    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tyramine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
N    O
-    O
methyltyramine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
vitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
7-O    O
-    O
methylvitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
xanthotoxol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-Calculation105802185
and    O
O    O
-    O
methylxanthotoxol    O
.    O

DPD    O
is    O
produced    O
by    O
degradation    O
of    O
"S"-adenosylhomocysteine    B-Calculation105802185
by    O
the    O
action    O
of    O
the    O
enzyme    O
"    O
S    O
"-    O
ribosylhomocysteinase    O
.    O

The    O
pathway    O
for    O
the    O
synthesis    O
of    O
creatineArg    O
-    O
Arginine    O
;    O
GATM    O
-    O
Glycine    O
amidinotransferase    O
;    O
GAMT    O
-    O
Guanidinoacetate    O
N    O
-    O
methyltransferase    O
;    O
Gly    O
-    O
Glycine    O
;    O
Met    O
-    O
Methionine    O
;    O
SAH    O
-    O
S-adenosyl    B-Calculation105802185
homocysteine    I-Calculation105802185
;    O
SAM    O
-    O
S    O
-    O
adenosyl    O
methionine    O
.    O

According    O
to    O
the    O
official    O
blog    O
of    O
Autism    O
Speaks    O
,    O
James    O
found    O
that    O
autistic    O
children    O
exhibit    O
abnormal    O
folate    O
metabolism    O
that    O
is    O
detectable    O
by    O
higher    O
levels    O
of    O
plasma    O
homocysteine    O
,    O
adenosine    O
,    O
and    O
S-adenosyl-L-homocysteine    B-Calculation105802185
in    O
the    O
mothers    O
of    O
these    O
children    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-homocysteine    B-Calculation105802185
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
inosyl    O
-    O
L    O
-    O
homocysteine    O
and    O
NH3    O
.    O

The    O
5    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
,    O
malonyl    O
-    O
CoA    O
,    O
NADPH    O
,    O
H+    O
,    O
and    O
S    O
-    O
adenosyl    O
-    O
L    O
-    O
methionine    O
,    O
whereas    O
its    O
6    O
products    O
are    O
dihydromonacolin    O
L    O
,    O
CoA    O
,    O
CO2    O
,    O
NADP+    O
,    O
S-adenosyl-L-homocysteine    B-Calculation105802185
,    O
and    O
H2O.    O

Abbreviations    O
:    O
S-Adenosyl-L-homocysteine    B-Calculation105802185
(    O
SAH    O
)    O
,    O
S    O
-    O
adenosyl    O
-    O
L    O
-    O
methionine    O
(    O
SAM    O
)    O
,    O
DNA    O
methyltransferase    O
(    O
DNA    O
MTase    O
)    O
,    O
Uracil    O
-    O
DNA    O
glycosylase    O
(    O
UNG    O
)    O
.    O

Acetylmuramic    O
acid    O
,    B-Calculation105802185
or    I-Calculation105802185
"'MurNAc    I-Calculation105802185
,    O
is    O
the    O
ether    O
of    O
lactic    O
acid    O
and    O
"    O
N    O
"-    O
acetylglucosamine    O
with    O
a    O
chemical    O
formula    O
of    O
C11H19NO8    O
.    O

(    O
1    O
)    O
formation    O
of    O
UDP    O
-    O
N-acetylmuramic    B-Calculation105802185
acid    I-Calculation105802185
(    O
UDPMurNAc    O
)    O
from    O
N    O
-    O
acetylglucosamine    O
(    O
GlcNAc    O
)    O
.    O

These    O
four    O
Mur    O
ligases    O
are    O
responsible    O
for    O
the    O
successive    O
additions    O
of    O
L    O
-    O
alanine    O
,    O
D    O
-    O
glutamate    O
,    O
meso    O
-    O
diaminopimelate    O
or    O
L    O
-    O
lysine    O
,    O
and    O
D    O
-    O
alanyl    O
-    O
D    O
-    O
alanine    O
to    O
UDP    O
-    O
N-acetylmuramic    B-Calculation105802185
acid    I-Calculation105802185
.    O

The    O
Darboux    B-Calculation105802185
integral    I-Calculation105802185
,    O
which    O
is    O
constructed    O
using    O
Darboux    O
sums    O
and    O
is    O
equivalent    O
to    O
a    O
Riemann    B-Calculation105802185
integral    I-Calculation105802185
,    O
meaning    O
that    O
a    O
function    O
is    O
Darboux    O
-    O
integrable    O
if    O
and    O
only    O
if    O
it    O
is    O
Riemann    O
-    O
integrable    O
.    O

Darboux    B-Calculation105802185
integral    I-Calculation105802185

Write    O
for    O
the    O
solid    B-Calculation105802185
of    I-Calculation105802185
revolution    I-Calculation105802185
of    O
the    O
graph    O
about    O
the    O
-axis    O
.    O

Computations    O
of    O
volumes    O
of    O
solids    B-Calculation105802185
of    I-Calculation105802185
revolution    I-Calculation105802185
can    O
usually    O
be    O
done    O
with    O
disk    O
integration    O
or    O
shell    O
integration    O
.    O

For    O
all    O
"    O
d    O
"    O
for    O
bodies    B-Calculation105802185
of    I-Calculation105802185
revolution    I-Calculation105802185

In    O
3-dimensions    O
,    O
a    O
surface    O
or    O
solid    B-Calculation105802185
of    I-Calculation105802185
revolution    I-Calculation105802185
has    O
circular    O
symmetry    O
around    O
an    O
axis    O
,    O
also    O
called    O
cylindrical    O
symmetry    O
.    O

In    O
geometry    O
,    O
a    O
superegg    O
is    O
a    O
solid    B-Calculation105802185
of    I-Calculation105802185
revolution    I-Calculation105802185
obtained    O
by    O
rotating    O
an    O
elongated    O
superellipse    O
with    O
exponent    O
greater    O
than    O
2    O
around    O
its    O
longest    O
axis    O
.    O

Pearson–Cunningham    B-Calculation105802185
function    I-Calculation105802185

Orthanilic    B-Calculation105802185
acid    I-Calculation105802185

Thermolysin    O
complexed    O
with    O
the    O
inhibitor    O
(    O
"    O
thiorphan    B-Calculation105802185
are    O
isomeric    O
thiol    O
-    O
containing    O
inhibitors    O
of    O
endopeptidase    O
EC    O
24    O
-    O
11    O
(    O
also    O
called    O
"    O
enkephalinase    O
"    O
)    O
.    O

carglumic    B-Calculation105802185
acid    I-Calculation105802185
(    O
USAN    O
)    O

Three-point    B-Calculation105802185
estimation    I-Calculation105802185

Acivicin    B-Calculation105802185
is    O
an    O
analog    O
of    O
glutamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
agaritine    B-Calculation105802185
and    O
acceptor    O
,    O
whereas    O
its    O
two    O
products    O
are    O
4-hydroxymethylphenylhydrazine    O
and    O
gamma    O
-    O
L    O
-    O
glutamyl    O
-    O
acceptor    O
.    O

Fieller's    B-Calculation105802185
theorem    I-Calculation105802185
can    O
be    O
used    O
to    O
compute    O
confidence    O
intervals    O
of    O
these    O
ratios    O
.    O

Indeed    O
,    O
this    O
is    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
for    O
a    O
Riemann–Stieltjes    B-Calculation105802185
integral    I-Calculation105802185
.    O

Although    O
seemingly    O
ill    O
-    O
defined    O
,    O
derivatives    O
of    O
the    O
indicator    O
function    O
can    O
formally    O
be    O
defined    O
using    O
the    O
theory    O
of    O
distributions    O
or    O
generalized    O
functions    O
:    O
one    O
can    O
obtain    O
a    O
well    O
-    O
defined    O
prescription    O
by    O
postulating    O
that    O
the    O
Laplacian    O
of    O
the    O
indicator    O
,    O
for    O
example    O
,    O
is    O
defined    O
by    O
two    O
integrations    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
when    O
it    O
appears    O
under    O
an    O
integral    O
sign    O
.    O

We    O
can    O
compute    O
it    O
here    O
using    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
.    O

The    O
Riemann    O
–    O
Stieltjes    O
integral    O
admits    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
in    O
the    O
form    O

After    O
using    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
in    O
the    O
definition    O
of    O
the    O
Fourier    O
coefficient    O
we    O
have    O
that    O

Integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
,    O
a    O
method    O
for    O
computing    O
the    O
integral    O
of    O
a    O
product    O
of    O
functions    O

with    O
0    O
"    O
n"+1    O
=    O
"    O
B'n"+1    O
−    O
"    O
B'n    O
"    O
,    O
and    O
in    O
performing    O
a    O
transformation    O
similar    O
to    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
(    O
called    O
summation    O
by    O
parts    O
)    O
,    O
that    O
relates    O
the    O
given    O
series    O
to    O
the    O
absolutely    O
convergent    O
series    O

Integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185

Integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185

By    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
we    O
find    O
the    O
recurrence    O
relations    O

Given    O
boundary    O
conditions    O
,    O
basically    O
a    O
specification    O
of    O
the    O
value    O
of    O
at    O
the    O
boundary    O
if    O
"    O
M    O
"    O
is    O
compact    O
or    O
some    O
limit    O
on    O
as    O
"    O
x    O
"    O
→    O
∞    O
(    O
this    O
will    O
help    O
in    O
doing    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
)    O
,    O
the    O
subspace    O
of    O
consisting    O
of    O
functions    O
,    O
,    O
such    O
that    O
all    O
functional    O
derivatives    O
of    O
"    O
S    O
"    O
at    O
are    O
zero    O
and    O
satisfies    O
the    O
given    O
boundary    O
conditions    O
is    O
the    O
subspace    O
of    O
on    O
shell    O
solutions    O
.    O

In    O
connection    O
with    O
differential    O
operators    O
it    O
is    O
common    O
to    O
use    O
inner    O
products    O
and    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
.    O

so    O
the    O
deflection    O
satisfies    O
the    O
equation    O
Using    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
and    O
the    O
boundary    O
conditions    O
,    O
one    O
can    O
see    O
that    O

Moreover    O
,    O
for    O
every    O
"    O
u    O
"    O
in    O
"    O
D"("A    O
"    O
)    O
,    O
using    O
integration    B-Calculation105802185
by    I-Calculation105802185
parts    I-Calculation105802185
,    O

OCD    O
has    O
been    O
associated    O
with    O
reduced    O
N-Acetylaspartic    B-Calculation105802185
acid    I-Calculation105802185
in    O
the    O
mPFC    O
,    O
which    O
is    O
thought    O
to    O
reflect    O
neuron    O
density    O
or    O
functionality    O
,    O
although    O
the    O
exact    O
interpretation    O
has    O
not    O
been    O
established    O
.    O

Moreover    O
,    O
evidence    O
suggests    O
that    O
adverse    O
changes    O
in    O
the    O
level    O
of    O
biomarkers    O
of    O
metabolic    O
integrity    O
and    O
synthesis    O
occur    O
in    O
recreational    O
users    O
,    O
such    O
as    O
a    O
reduction    O
in    O
"N"-acetylaspartate    B-Calculation105802185
and    O
creatine    O
levels    O
and    O
elevated    O
levels    O
of    O
choline    O
and    O
myoinositol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
and    O
L    O
-    O
aspartate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N-acetyl-L-aspartate    B-Calculation105802185
.    O

The    O
forms    O
below    O
normally    O
assume    O
the    O
Cauchy    B-Calculation105802185
principal    I-Calculation105802185
value    I-Calculation105802185
around    O
a    O
singularity    O
in    O
the    O
value    O
of    O
"    O
C    O
"    O
but    O
this    O
is    O
not    O
in    O
general    O
necessary    O
.    O

and    O
so    O
generalize    O
the    O
Cauchy    B-Calculation105802185
principal    I-Calculation105802185
value    I-Calculation105802185
distribution    O
of    O
1/"x    O
"    O
that    O
arises    O
in    O
the    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
.    O

Cauchy    B-Calculation105802185
principal    I-Calculation105802185
value    I-Calculation105802185

Cauchy    B-Calculation105802185
principal    I-Calculation105802185
value    I-Calculation105802185

Cauchy    B-Calculation105802185
principal    I-Calculation105802185
value    I-Calculation105802185
,    O
a    O
method    O
for    O
assigning    O
values    O
to    O
certain    O
improper    O
integrals    O
which    O
would    O
otherwise    O
be    O
undefined    O

Here    O
,    O
denotes    O
the    O
principal    B-Calculation105802185
value    I-Calculation105802185
of    I-Calculation105802185
the    I-Calculation105802185
integral    I-Calculation105802185
.    O

In    O
1933    O
he    O
defined    O
the    O
Bochner    B-Calculation105802185
integral    I-Calculation105802185
,    O
as    O
it    O
is    O
now    O
called    O
,    O
for    O
vector    O
-    O
valued    O
functions    O
.    O

Bochner    B-Calculation105802185
integral    I-Calculation105802185

CPHPC    B-Calculation105802185
(    O
R-1-[6-[R-2-carboxy    O
-    O
pyrrolidin-1-yl]-6-oxo    O
-    O
hexanoyl    O
]    O
pyrrolidine-2-carboxylic    O
acid    O
)    O
is    O
a    O
proline    O
-    O
derived    O
small    O
molecule    O
able    O
to    O
strip    O
amyloid    O
P    O
(    O
AP    O
)    O
from    O
deposits    O
by    O
reducing    O
levels    O
of    O
circulating    O
serum    O
amyloid    O
P    O
(    O
SAP    O
)    O
.    O

m    O
-    O
Hydroxyphenylglycine    O
and    O
3,5-dihydroxyphenylglycine    B-Calculation105802185
are    O
two    O
amino    O
acids    O
that    O
can    O
be    O
isolated    O
from    O
the    O
latex    O
of    O
"    O
E.    O
helioscopia    O
"    O
.    O

N    O
-    O
acetylglutamate    O
synthase    O
(    O
NAGS    O
)    O
is    O
an    O
enzyme    O
that    O
catalyses    O
the    O
production    O
of    O
"N"-Acetylglutamate    B-Calculation105802185
(    O
NAG    O
)    O
from    O
glutamate    O
and    O
acetyl    O
-    O
CoA.    O

Nova    B-Calculation105802185
Linux    I-Calculation105802185

Nova    B-Calculation105802185
(operating    I-Calculation105802185
system)    I-Calculation105802185

Peter    O
Gustav    O
Lejeune    O
Dirichlet    O
publishes    O
a    O
memoir    O
giving    O
the    O
Dirichlet    O
conditions    O
,    O
showing    O
for    O
which    O
functions    O
the    O
convergence    O
of    O
the    O
Fourier    O
series    O
holds    O
;    O
introducing    O
Dirichlet    O
's    O
test    O
for    O
the    O
convergence    O
of    O
series    O
;    O
the    O
Dirichlet    O
function    O
as    O
an    O
example    O
that    O
not    O
any    O
function    O
is    O
integrable    O
;    O
and    O
,    O
in    O
the    O
proof    O
of    O
the    O
theorem    O
for    O
the    O
Fourier    O
series    O
,    O
the    O
Dirichlet    O
kernel    O
and    O
Dirichlet    B-Calculation105802185
integral    I-Calculation105802185
.    O

where    O
the    O
imaginary    O
part    O
of    O
a    O
complex    O
number    O
is    O
given    O
by    O
.The    O
integral    O
may    O
be    O
not    O
Lebesgue-integrable    B-Calculation105802185
;    O
for    O
example    O
,    O
when    O
"    O
X    O
"    O
is    O
the    O
discrete    O
random    O
variable    O
that    O
is    O
always    O
0    O
,    O
it    O
becomes    O
the    O
Dirichlet    B-Calculation105802185
integral    I-Calculation105802185
.    O

Studies    O
have    O
shown    O
this    O
treatment    O
combined    O
with    O
valacyclovir    B-Calculation105802185
to    O
be    O
effective    O
in    O
combating    O
HSV-1    O
and    O
eventually    O
returning    O
lymphocyte    O
counts    O
to    O
normal    O
.    O

Since    O
herpes    O
infections    O
often    O
lead    O
to    O
pleocytosis    O
,    O
aciclovir    O
and    O
valacyclovir    B-Calculation105802185
are    O
commonly    O
prescribed    O
.    O

Valaciclovir    B-Calculation105802185
,    O
also    O
spelled    O
valacyclovir    B-Calculation105802185
,    O
is    O
an    O
antiviral    O
drug    O
used    O
in    O
the    O
management    O
of    O
herpes    O
simplex    O
,    O
herpes    O
zoster    O
(    O
shingles    O
)    O
,    O
and    O
herpes    O
B.    O

Purine    O
analogues    O
of    O
guanine    O
:    O
Aciclovir    O
,    O
Famciclovir    O
,    O
Ganciclovir    O
,    O
Penciclovir    O
,    O
Valaciclovir    B-Calculation105802185
,    O
Valganciclovir    B-Calculation105802185

9-Carboxymethoxymethylguanine    O
(    O
CMMG    O
)    O
is    O
a    O
compound    O
which    O
is    O
known    O
as    O
the    O
principal    O
metabolite    O
of    O
the    O
antiviral    O
drug    O
acyclovir    O
(    O
and    O
its    O
prodrug    O
valacyclovir    B-Calculation105802185
)    O
,    O
and    O
has    O
been    O
suggested    O
as    O
the    O
causative    O
agent    O
in    O
the    O
neuropsychiatric    O
side    O
effects    O
sometimes    O
associated    O
with    O
these    O
drugs    O
.    O

In    O
the    O
case    O
of    O
herpetic    O
uveitis    O
,    O
anti    O
-    O
viral    O
medications    O
,    O
such    O
as    O
valaciclovir    B-Calculation105802185
or    O
aciclovir    O
,    O
may    O
be    O
administered    O
to    O
treat    O
the    O
causative    O
viral    O
infection    O
.    O

68–95–99.7    B-Calculation105802185
rule    I-Calculation105802185
,    O
a    O
concept    O
in    O
statistics    O

In    O
the    O
case    O
of    O
normally    O
distributed    O
data    O
,    O
the    O
three    B-Calculation105802185
sigma    I-Calculation105802185
rule    I-Calculation105802185
means    O
that    O
roughly    O
1    O
in    O
22    O
observations    O
will    O
differ    O
by    O
twice    O
the    O
standard    O
deviation    O
or    O
more    O
from    O
the    O
mean    O
,    O
and    O
1    O
in    O
370    O
will    O
deviate    O
by    O
three    O
times    O
the    O
standard    O
deviation    O
.    O

The    O
3    B-Calculation105802185
sigma    I-Calculation105802185
range    O
is    O
six    O
times    O
the    O
standard    O
deviation    O
:    O
three    O
above    O
the    O
mean    O
,    O
and    O
three    O
below    O
.    O

The    O
relation    O
between    O
and    O
is    O
referred    O
to    O
as    O
a    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
.    O

The    O
case    O
of    O
is    O
not    O
interesting    O
here    O
as    O
convergence    O
follows    O
for    O
in    O
the    O
most    O
difficult    O
case    O
as    O
a    O
consequence    O
of    O
the    O
boundedness    O
of    O
the    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
and    O
an    O
argument    O
of    O
Marcel    O
Riesz    O
.    O

With    O
the    O
help    O
of    O
a    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
the    O
cosine    O
term    O
is    O
changed    O
into    O
a    O
sine    O
term    O
.    O

Many    O
familiar    O
operators    O
,    O
such    O
as    O
translations    O
and    O
differentiation    O
,    O
are    O
multiplier    O
operators    O
,    O
although    O
there    O
are    O
many    O
more    O
complicated    O
examples    O
such    O
as    O
the    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
.    O

An    O
example    O
of    O
a    O
multiplier    O
operator    O
acting    O
on    O
functions    O
on    O
the    O
real    O
line    O
is    O
the    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
.    O

The    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
is    O
bounded    O
only    O
for    O
"    O
p    O
"    O
strictly    O
between    O
1    O
and    O
∞.    O
The    O
fact    O
that    O
it    O
is    O
unbounded    O
on    O
"    O
L"∞    O
is    O
easy    O
,    O
since    O
it    O
is    O
well    O
known    O
that    O
the    O
Hilbert    O
transform    O
of    O
a    O
step    O
function    O
is    O
unbounded    O
.    O

where    O
is    O
the    O
derivative    O
of    O
the    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
of    O

and    O
so    O
generalize    O
the    O
Cauchy    B-Calculation105802185
principal    I-Calculation105802185
value    I-Calculation105802185
distribution    O
of    O
1/"x    O
"    O
that    O
arises    O
in    O
the    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
.    O

The    O
theory    O
is    O
particularly    O
simple    O
in    O
two    O
dimensions    O
—    O
the    O
case    O
treated    O
in    O
detail    O
in    O
this    O
article    O
—    O
where    O
it    O
is    O
related    O
to    O
complex    O
function    O
theory    O
,    O
the    O
conjugate    O
Beurling    B-Calculation105802185
transform    I-Calculation105802185
or    O
complex    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
and    O
the    O
Fredholm    O
eigenvalues    O
of    O
bounded    O
planar    O
domains    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
1-deoxy-D-xylulose    B-Calculation105802185
5-phosphate    I-Calculation105802185
and    O
3-amino-2-oxopropyl    O
phosphate    O
,    O
whereas    O
its    O
3    O
products    O
are    O
pyridoxine    O
5'-phosphate    O
,    O
phosphate    O
,    O
and    O
H2O.    O

:    O
H03BX02    O
Dibromotyrosine    B-Calculation105802185

It    O
is    O
formed    O
by    O
6-phosphogluconolactonase    O
,    O
and    O
acted    O
upon    O
by    O
phosphogluconate    O
dehydrogenase    O
to    O
produce    O
ribulose    B-Calculation105802185
5-phosphate    I-Calculation105802185
.    O

The    O
last    O
step    O
of    O
the    O
oxidative    O
reactions    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
is    O
the    O
production    O
of    O
ribulose    B-Calculation105802185
5-phosphate    I-Calculation105802185
.    O

It    O
is    O
a    O
ketose    O
sugar    O
formed    O
from    O
ribulose-5-phosphate    B-Calculation105802185
.    O

Oscillatory    B-Calculation105802185
integral    I-Calculation105802185
operator    I-Calculation105802185

Hepapressin    B-Calculation105802185
is    O
an    O
amino    O
acid    O
complex    O
prepared    O
from    O
Argentinian    O
bovine    O
liver    O
.    O

Procyanidin    O
B2    O
has    O
been    O
shown    O
to    O
inhibit    O
the    O
formation    O
of    O
the    O
advanced    O
glycation    O
end    O
-    O
products    O
pentosidine    O
,    O
carboxymethyllysine    B-Calculation105802185
(    O
CML    O
)    O
,    O
and    O
methylglyoxal    O
(    O
MGO    O
)    O
.    O

These    O
probabilistic    O
techniques    O
are    O
closely    O
related    O
to    O
Approximate    B-Calculation105802185
Bayesian    I-Calculation105802185
Computation    I-Calculation105802185
(    O
ABC    O
)    O
.    O

Approximate    B-Calculation105802185
Bayesian    I-Calculation105802185
computation    I-Calculation105802185
,    O
a    O
family    O
of    O
statistical    O
techniques    O

3,5,3'-Triiodothyronamine    B-Calculation105802185
(    O
T3AM    O
)    O

The    O
fundamental    B-Calculation105802185
theorem    I-Calculation105802185
of    I-Calculation105802185
line    I-Calculation105802185
integrals    I-Calculation105802185
,    O
says    O
that    O
a    O
line    B-Calculation105802185
integral    I-Calculation105802185
through    O
a    O
gradient    O
field    O
can    O
be    O
evaluated    O
by    O
evaluating    O
the    O
original    O
scalar    O
field    O
at    O
the    O
endpoints    O
of    O
the    O
curve    O
.    O

The    O
most    O
familiar    O
extensions    O
of    O
the    O
fundamental    O
theorem    O
of    O
calculus    O
in    O
higher    O
dimensions    O
are    O
the    O
divergence    O
theorem    O
and    O
the    O
gradient    B-Calculation105802185
theorem    I-Calculation105802185
.    O

Gradient    B-Calculation105802185
theorem    I-Calculation105802185

One    O
domain    O
facilitates    O
the    O
ATP    O
-    O
grasp    O
mechanism    O
and    O
the    O
other    O
is    O
the    O
catalytic    O
active    O
site    O
for    O
γ-glutamylcysteine    B-Calculation105802185
.    O

In    O
applied    O
statistics    O
,    O
the    O
Morris    B-Calculation105802185
method    I-Calculation105802185
for    O
global    O
sensitivity    O
analysis    O
is    O
a    O
so    O
-    O
called    O
one    O
-    O
step    O
-    O
at    O
-    O
a    O
-    O
time    O
method    O
(    O
OAT    O
)    O
,    O
meaning    O
that    O
in    O
each    O
run    O
only    O
one    O
input    O
parameter    O
is    O
given    O
a    O
new    O
value    O
.    O

:    O
(    O
both    O
by    O
Stirling's    B-Calculation105802185
formula    I-Calculation105802185
)    O
.    O

First    O
,    O
according    O
to    O
Stirling's    B-Calculation105802185
formula    I-Calculation105802185
,    O
we    O
can    O
replace    O
the    O
factorial    O
of    O
a    O
large    O
number    O
"    O
n    O
"    O
with    O
the    O
approximation    O
:    O

Using    O
Stirling's    B-Calculation105802185
approximation    I-Calculation105802185
,    O
we    O
can    O
write    O
:    O

The    O
formula    O
is    O
a    O
modification    O
of    O
Stirling's    B-Calculation105802185
approximation    I-Calculation105802185
,    O
and    O
has    O
the    O
form    O

Stirling's    B-Calculation105802185
approximation    I-Calculation105802185

In    O
this    O
case    O
,    O
one    O
may    O
make    O
use    O
of    O
Stirling's    B-Calculation105802185
approximation    I-Calculation105802185
to    O
the    O
factorial    O
,    O
and    O
write    O

Stirling's    B-Calculation105802185
formula    I-Calculation105802185
was    O
discovered    O
and    O
proven    O
by    O
Abraham    O
de    O
Moivre    O
circa    O
1733    O
.    O

Comparison    O
of    O
De    O
Moivre    O
's    O
approximation    O
with    O
the    O
factorial    O
;    O
the    O
formula    O
is    O
now    O
known    O
as    O
Stirling's    B-Calculation105802185
approximation    I-Calculation105802185
.    O

The    O
derivation    O
uses    O
the    O
Stirling's    B-Calculation105802185
approximation    I-Calculation105802185
,    O
.    O

Remacemide    B-Calculation105802185
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
low    O
-    O
affinity    O
NMDA    O
antagonist    O
with    O
sodium    O
channel    O
blocking    O
properties    O
.    O

Compounds    O
that    O
have    O
failed    O
to    O
prevent    O
or    O
slow    O
progression    O
of    O
Huntington    O
's    O
disease    O
in    O
human    O
trials    O
include    O
remacemide    B-Calculation105802185
,    O
coenzyme    O
Q10    O
,    O
riluzole    O
,    O
creatine    O
,    O
minocycline    O
,    O
ethyl    O
-    O
EPA    O
,    O
phenylbutyrate    O
and    O
dimebon    O
.    O

In    O
numerical    O
mathematics    O
,    O
interval    B-Calculation105802185
propagation    I-Calculation105802185
or    O
interval    B-Calculation105802185
constraint    I-Calculation105802185
propagation    I-Calculation105802185
is    O
the    O
problem    O
of    O
contracting    O
interval    O
domains    O
associated    O
to    O
variables    O
of    O
R    B-Calculation105802185
without    O
removing    O
any    O
value    O
that    O
is    O
consistent    O
with    O
a    O
set    O
of    O
constraints    O
(    O
i.e.    O
,    O
equations    O
or    O
inequalities    O
)    O
.    O

The    O
theorem    O
was    O
first    O
established    O
by    O
Swedish    O
mathematician    O
Ivar    O
Bendixson    O
in    O
1901    O
and    O
further    O
refined    O
by    O
French    O
mathematician    O
Henri    O
Dulac    O
in    O
1933    O
using    O
Green's    B-Calculation105802185
theorem    I-Calculation105802185
.    O

Then    O
by    O
Green's    B-Calculation105802185
Theorem    I-Calculation105802185
,    O

Self    O
-    O
taught    O
English    O
mathematician    O
George    O
Green    O
publishes    O
"    O
An    O
Essay    O
on    O
the    O
Application    O
of    O
Mathematical    O
Analysis    O
to    O
the    O
Theories    O
of    O
Electricity    O
and    O
Magnetism    O
''    O
in    O
Nottingham    O
,    O
the    O
first    O
mathematical    O
theory    O
of    O
electricity    O
and    O
magnetism    O
,    O
introducing    O
a    O
form    O
of    O
divergence    O
theorem    O
(    O
a    O
version    O
of    O
Green's    B-Calculation105802185
theorem    I-Calculation105802185
)    O
,    O
the    O
idea    O
of    O
potential    O
theory    O
,    O
and    O
the    O
concept    O
of    O
what    O
will    O
come    O
to    O
be    O
called    O
Green    O
's    O
functions    O
.    O

Bernhard    O
Riemann    O
provides    O
a    O
proof    O
of    O
Green's    B-Calculation105802185
theorem    I-Calculation105802185
in    O
his    O
inaugural    O
dissertation    O
.    O

:    O
Essay    O
conceived    O
several    O
key    O
ideas    O
,    O
among    O
them    O
a    O
theorem    O
similar    O
to    O
the    O
modern    O
Green's    B-Calculation105802185
theorem    I-Calculation105802185
,    O
the    O
idea    O
of    O
potential    O
functions    O
,    O
and    O
the    O
concept    O
of    O
what    O
are    O
now    O
called    O
Green    O
's    O
functions    O
.    O

The    O
exterior    O
derivative    O
plays    O
the    O
role    O
of    O
the    O
gradient    O
and    O
curl    O
of    O
vector    O
calculus    O
,    O
and    O
Stokes    O
'    O
theorem    O
simultaneously    O
generalizes    O
the    O
three    O
theorems    O
of    O
vector    O
calculus    O
:    O
the    O
divergence    O
theorem    O
,    O
Green's    B-Calculation105802185
theorem    I-Calculation105802185
,    O
and    O
the    O
Kelvin    O
-    O
Stokes    O
theorem    O
.    O

Green's    B-Calculation105802185
theorem    I-Calculation105802185
for    O
a    O
bounded    O
region    O
Ω    O
in    O
the    O
plane    O
with    O
smooth    O
boundary    O
∂Ω    O
states    O
that    O

His    O
main    O
field    O
of    O
work    O
has    O
been    O
p    O
-    O
adic    O
Nevanlinna    O
theory    O
,    O
for    O
example    O
proving    O
part    O
of    O
a    O
non    O
-    O
Archimedean    O
version    O
of    O
Green's    B-Calculation105802185
theorem    I-Calculation105802185
(    O
AMS    O
,    O
1992    O
,    O
503    O
-    O
509    O
)    O
.    O

In    O
the    O
high    O
-    O
dimensional    O
case    O
,    O
the    O
Newtonian    O
potential    O
is    O
the    O
opposite    O
of    O
the    O
Riesz    B-Calculation105802185
potential    I-Calculation105802185
.    O

Riesz    B-Calculation105802185
potential    I-Calculation105802185

If    O
"    O
g    O
"    O
should    O
happen    O
to    O
be    O
everywhere    O
differentiable    O
,    O
then    O
the    O
Riemann    O
–    O
Stieltjes    O
integral    O
may    O
still    O
be    O
different    O
from    O
the    O
Riemann    B-Calculation105802185
integral    I-Calculation105802185
of    O
given    O
by    O

Alternatively    O
,    O
if    O
is    O
merely    O
Riemann    B-Calculation105802185
integrable    I-Calculation105802185
,    O
then    O
is    O
continuous    O
on    O
(    O
but    O
not    O
necessarily    O
differentiable    O
)    O
.    O

If    O
is    O
Riemann    B-Calculation105802185
integrable    I-Calculation105802185
on    O
then    O

This    O
is    O
a    O
limit    O
proof    O
by    O
Riemann    B-Calculation105802185
sums    I-Calculation105802185
.    O

By    O
taking    O
the    O
limit    O
of    O
the    O
expression    O
as    O
the    O
norm    O
of    O
the    O
partitions    O
approaches    O
zero    O
,    O
we    O
arrive    O
at    O
the    O
Riemann    B-Calculation105802185
integral    I-Calculation105802185
.    O

The    O
Darboux    B-Calculation105802185
integral    I-Calculation105802185
,    O
which    O
is    O
constructed    O
using    O
Darboux    O
sums    O
and    O
is    O
equivalent    O
to    O
a    O
Riemann    B-Calculation105802185
integral    I-Calculation105802185
,    O
meaning    O
that    O
a    O
function    O
is    O
Darboux    O
-    O
integrable    O
if    O
and    O
only    O
if    O
it    O
is    O
Riemann    O
-    O
integrable    O
.    O

In    O
some    O
cases    O
such    O
integrals    O
may    O
be    O
defined    O
by    O
considering    O
the    O
limit    O
of    O
a    O
sequence    O
of    O
proper    O
Riemann    B-Calculation105802185
integral    I-Calculation105802185
on    O
progressively    O
larger    O
intervals    O
.    O

Riemann    B-Calculation105802185
integral    I-Calculation105802185

The    O
functions    O
1    O
,    O
sin("nx    O
"    O
)    O
,    O
cos("nx    O
"    O
)    O
:    O
"    O
n    O
"    O
=    O
1    O
,    O
2    O
,    O
3    O
,    O
...    O
are    O
orthogonal    O
with    O
respect    O
to    O
Riemann    B-Calculation105802185
integration    I-Calculation105802185
on    O
the    O
intervals    O
,    O
,    O
or    O
any    O
other    O
closed    O
interval    O
of    O
length    O
2π.    O
This    O
fact    O
is    O
a    O
central    O
one    O
in    O
Fourier    O
series    O
.    O

He    O
called    O
on    O
Brownian    O
motion    O
to    O
conjecture    O
the    O
continuity    O
of    O
his    O
Riemann    B-Calculation105802185
integral    I-Calculation105802185
but    O
did    O
not    O
explain    O
what    O
Brownian    O
motion    O
and    O
ore    O
deposits    O
have    O
in    O
common    O
.    O

A    O
typical    O
example    O
of    O
a    O
linear    O
functional    O
is    O
integration    O
:    O
the    O
linear    O
transformation    O
defined    O
by    O
the    O
Riemann    B-Calculation105802185
integral    I-Calculation105802185

The    O
Riemann    B-Calculation105802185
integral    I-Calculation105802185
is    O
a    O
linear    O
functional    O
on    O
the    O
vector    O
space    O
of    O
Riemann    O
-    O
integrable    O
functions    O
from    O
to    O
.    O

The    O
T    O
-    O
DNA    O
carries    O
genes    O
for    O
the    O
biosynthetic    O
enzymes    O
for    O
the    O
production    O
of    O
unusual    O
amino    O
acids    O
,    O
typically    O
octopine    B-Calculation105802185
or    O
nopaline    B-Calculation105802185
.    O

Bessel    B-Calculation105802185
potential    I-Calculation105802185

There    O
are    O
many    O
Linux    O
distributions    O
created    O
with    O
privacy    O
,    O
secrecy    O
,    O
network    O
anonymity    O
and    O
information    O
security    O
in    O
mind    O
,    O
including    O
Tails    O
,    O
Tin    B-Calculation105802185
Hat    I-Calculation105802185
Linux    I-Calculation105802185
and    O
Tinfoil    O
Hat    O
Linux    O
.    O

glutaurine    B-Calculation105802185
(    O
INN    O
)    O

At    O
this    O
stage    O
,    O
phosphoenolpyruvate    O
and    O
erythrose-4-phosphate    O
react    O
to    O
form    O
3-deoxy-D-arabinoheptulosonate-7-phosphate    B-Calculation105802185
(    O
DAHP    O
)    O
,    O
in    O
a    O
reaction    O
catalyzed    O
by    O
the    O
enzyme    O
DAHP    O
synthase    O
.    O

The    O
theory    O
is    O
particularly    O
simple    O
in    O
two    O
dimensions    O
—    O
the    O
case    O
treated    O
in    O
detail    O
in    O
this    O
article    O
—    O
where    O
it    O
is    O
related    O
to    O
complex    O
function    O
theory    O
,    O
the    O
conjugate    O
Beurling    B-Calculation105802185
transform    I-Calculation105802185
or    O
complex    O
Hilbert    B-Calculation105802185
transform    I-Calculation105802185
and    O
the    O
Fredholm    O
eigenvalues    O
of    O
bounded    O
planar    O
domains    O
.    O

The    O
"    O
sophomore's    B-Calculation105802185
dream    I-Calculation105802185
"    O
:    O

Loosely    O
put    O
,    O
the    O
first    O
part    O
deals    O
with    O
the    O
derivative    O
of    O
an    O
antiderivative    B-Calculation105802185
,    O
while    O
the    O
second    O
part    O
deals    O
with    O
the    O
relationship    O
between    O
antiderivatives    O
and    O
definite    O
integrals    O
.    O

Indefinite    O
integration    O
,    O
the    O
computation    O
antiderivative    B-Calculation105802185

Even    O
if    O
the    O
limit    O
of    O
the    O
power    O
series    O
is    O
not    O
considered    O
,    O
if    O
the    O
terms    O
support    O
appropriate    O
structure    O
then    O
it    O
is    O
possible    O
to    O
define    O
operations    O
such    O
as    O
addition    O
,    O
multiplication    O
,    O
derivative    O
,    O
antiderivative    B-Calculation105802185
for    O
power    O
series    O
"    O
formally    O
"    O
,    O
treating    O
the    O
symbol    O
"    O
+    O
"    O
as    O
if    O
it    O
corresponded    O
to    O
addition    O
.    O

For    O
this    O
reason    O
,    O
the    O
term    O
"    O
integral    O
"    O
may    O
also    O
refer    O
to    O
the    O
related    O
notion    O
of    O
the    O
antiderivative    B-Calculation105802185
,    O
a    O
function    O
whose    O
derivative    O
is    O
the    O
given    O
function    O
.    O

In    O
this    O
case    O
,    O
it    O
is    O
called    O
an    O
"    O
indefinite    B-Calculation105802185
integral    I-Calculation105802185
"    O
and    O
is    O
written    O
:    O

the    O
integral    O
is    O
called    O
an    O
indefinite    O
integral    O
,    O
which    O
represents    O
a    O
class    O
of    O
functions    O
(    O
the    O
antiderivative    B-Calculation105802185
)    O
whose    O
derivative    O
is    O
the    O
integrand    O
.    O

Let    O
be    O
a    O
real    O
-    O
valued    O
function    O
defined    O
on    O
a    O
closed    O
interval    O
that    O
admits    O
an    O
antiderivative    B-Calculation105802185
on    O
.    O

Antiderivative    B-Calculation105802185

diverges    O
because    O
,    O
using    O
the    O
natural    O
logarithm    O
,    O
its    O
antiderivative    B-Calculation105802185
,    O
and    O
the    O
fundamental    O
theorem    O
of    O
calculus    O
,    O
we    O
get    O

The    O
last    O
relation    O
tells    O
us    O
,    O
that    O
,    O
for    O
fixed    O
"    O
s    O
"    O
,    O
"    O
γ    O
"    O
is    O
a    O
primitive    B-Calculation105802185
or    I-Calculation105802185
antiderivative    I-Calculation105802185
of    O
the    O
holomorphic    O
function    O
"    O
z""s"−1    O
"    O
e"−"z    O
"    O
.    O

It    O
relates    O
to    O
the    O
forward    O
difference    O
operator    O
as    O
the    O
indefinite    B-Calculation105802185
integral    I-Calculation105802185
relates    O
to    O
the    O
derivative    O
.    O

The    O
first    O
volume    O
,    O
on    O
indefinite    B-Calculation105802185
integrals    I-Calculation105802185
,    O
was    O
published    O
by    O
Notdruck    O
(    O
Braunschweig    O
)    O
in    O
1944    O
and    O
by    O
Springer    O
in    O
1949    O
.    O

One    O
example    O
is    O
a    O
program    O
which    O
estimates    O
an    O
indefinite    B-Calculation105802185
integral    I-Calculation105802185
through    O
the    O
use    O
of    O
Simpson    O
's    O
Rule    O
;    O
this    O
can    O
be    O
found    O
within    O
the    O
user    O
manual    O
for    O
reference    O
.    O

Indefinite    B-Calculation105802185
integral    I-Calculation105802185
are    O
called    O
indefinite    O
because    O
their    O
solutions    O
are    O
only    O
unique    O
up    O
to    O
a    O
constant    O
.    O

In    O
Riemann    O
surface    O
theory    O
,    O
an    O
abelian    O
integral    O
is    O
a    O
function    O
related    O
to    O
the    O
indefinite    B-Calculation105802185
integral    I-Calculation105802185
of    O
a    O
differential    O
of    O
the    O
first    O
kind    O
.    O

Students    O
of    O
integral    O
calculus    O
know    O
that    O
f("x    O
"    O
)    O
=    O
'    O
'    O
x'p    O
"    O
has    O
an    O
algebraic    O
antiderivative    B-Calculation105802185
except    O
in    O
the    O
case    O
"    O
p    O
''    O
=    O
–1    O
corresponding    O
to    O
the    O
quadrature    O
of    O
the    O
hyperbola    O
.    O

In    O
mathematics    O
,    O
Liouville    O
's    O
theorem    O
,    O
originally    O
formulated    O
by    O
Joseph    O
Liouville    O
in    O
1833    O
to    O
1841    O
,    O
places    O
an    O
important    O
restriction    O
on    O
antiderivative    B-Calculation105802185
that    O
can    O
be    O
expressed    O
as    O
elementary    O
functions    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
L    O
-    O
threonine    O
and    O
fluoroacetaldehyde    O
,    O
whereas    O
its    O
two    O
products    O
are    O
acetaldehyde    O
and    O
4-fluoro-L-threonine    B-Calculation105802185
.    O

Then    O
the    O
"    O
n"th    O
repeated    B-Calculation105802185
integral    I-Calculation105802185
of    O
"    O
ƒ    O
"    O
based    O
at    O
"    O
a    O
"    O
,    O

It    O
is    O
also    O
known    O
as    O
cascara    B-Calculation105802185
,    O
from    O
the    O
Spanish    O
"    O
cáscara    O
"    O
,    O
meaning    O
"    O
husk    O
"    O
.    O

The    O
residue    O
of    O
lysine-142    O
in    O
the    O
active    O
site    O
of    O
transaldolase    O
forms    O
a    O
Schiff    O
base    O
with    O
the    O
keto    O
group    O
in    O
sedoheptulose-7-phosphate    B-Calculation105802185
after    O
deprotonation    O
by    O
another    O
active    O
site    O
residue    O
,    O
glutamate-106    O
.    O

Sedoheptulose    B-Calculation105802185
7-phosphate    I-Calculation105802185
is    O
an    O
intermediate    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
.    O

("S")-3,4-DCPG    B-Calculation105802185
:    O
agonist    O

The    O
convergence    O
of    O
stochastic    O
gradient    O
descent    O
has    O
been    O
analyzed    O
using    O
the    O
theories    O
of    O
convex    O
minimization    O
and    O
of    O
stochastic    B-Calculation105802185
approximation    I-Calculation105802185
.    O

It    O
is    O
a    O
type    O
of    O
stochastic    B-Calculation105802185
approximation    I-Calculation105802185
algorithm    O
.    O

Desoxyfructo-serotonin    B-Calculation105802185
is    O
a    O
leprostatic    O
agent    O
.    O

Purine    O
analogues    O
of    O
guanine    O
:    O
Aciclovir    O
,    O
Famciclovir    O
,    O
Ganciclovir    O
,    O
Penciclovir    O
,    O
Valaciclovir    B-Calculation105802185
,    O
Valganciclovir    B-Calculation105802185

In    O
terms    O
of    O
the    O
treatment    O
of    O
cytomegalovirus    O
retinitis    O
,    O
oral    O
valganciclovir    B-Calculation105802185
,    O
intravenous    O
ganciclovir    O
,    O
IV    O
foscarnet    O
,    O
and    O
IV    O
cidofovir    O
are    O
all    O
efficient    O
in    O
the    O
treatment    O
of    O
this    O
condition    O
.    O

where    O
the    O
integration    O
symbol    O
denotes    O
the    O
Jackson    B-Calculation105802185
integral    I-Calculation105802185
.    O

SystemRescueCD    B-Calculation105802185

For    O
Windows    O
users    O
,    O
Partimage    O
includes    O
experimental    O
support    O
for    O
NTFS    O
.    O
Partimage    O
supports    O
most    O
common    O
Linux    O
file    O
systems    O
,    O
and    O
can    O
be    O
found    O
in    O
many    O
Linux    O
distributions    O
,    O
including    O
Debian    O
and    O
the    O
live    O
distros    O
PING    O
,    O
Knoppix    O
and    O
SystemRescueCD    B-Calculation105802185
.    O

A    O
topical    O
cream    O
combining    O
alprostadil    O
with    O
the    O
permeation    O
enhancer    O
DDAIP    B-Calculation105802185
has    O
been    O
approved    O
in    O
Canada    O
under    O
the    O
brand    O
name    O
Vitaros    O
as    O
a    O
first    O
line    O
treatment    O
for    O
erectile    O
dysfunction    O
.    O

Some    O
cells    O
in    O
culture    O
grow    O
better    O
on    O
surfaces    O
coated    O
with    O
positive    O
charge    O
like    O
poly-L-lysine    B-Calculation105802185
or    O
polyornithine    O
or    O
Alcian    O
blue    O
.    O

From    O
studies    O
that    O
have    O
applied    O
this    O
method    O
to    O
poly    B-Calculation105802185
(L-lysine)    I-Calculation105802185
,    O
ELS    O
is    O
believed    O
to    O
monitor    O
fluctuation    O
mobilities    O
in    O
the    O
presence    O
of    O
solvents    O
with    O
varying    O
salt    O
concentrations    O
.    O

is    O
a    O
symbolic    O
result    O
for    O
an    O
indefinite    O
integral    O
(    O
here    O
C    O
is    O
a    O
constant    B-Calculation105802185
of    I-Calculation105802185
integration    I-Calculation105802185
)    O
,    O

integration    B-Calculation105802185
constant    I-Calculation105802185
,    O
are    O
actually    O
zero    O
.    O

Because    O
this    O
is    O
undefined    O
when    O
"    O
x    O
"    O
=    O
−"b    O
"    O
/    O
"    O
a    O
"    O
,    O
the    O
most    O
general    O
form    O
of    O
the    O
antiderivative    O
replaces    O
the    O
constant    B-Calculation105802185
of    I-Calculation105802185
integration    I-Calculation105802185
with    O
a    O
locally    O
constant    O
function    O
.    O

"    O
C    O
"    O
is    O
used    O
for    O
an    O
arbitrary    B-Calculation105802185
constant    I-Calculation105802185
of    I-Calculation105802185
integration    I-Calculation105802185
that    O
can    O
only    O
be    O
determined    O
if    O
something    O
about    O
the    O
value    O
of    O
the    O
integral    O
at    O
some    O
point    O
is    O
known    O
.    O

Throughout    O
this    O
article    O
the    O
constant    B-Calculation105802185
of    I-Calculation105802185
integration    I-Calculation105802185
is    O
omitted    O
for    O
brevity    O
.    O

where    O
C    O
is    O
the    O
constant    B-Calculation105802185
of    I-Calculation105802185
integration    I-Calculation105802185
,    O
and    O
hence    O

where    O
"    O
C    O
"    O
,    O
the    O
constant    B-Calculation105802185
of    I-Calculation105802185
integration    I-Calculation105802185
,    O
is    O
an    O
arbitrary    O
fixed    O
real    O
number    O
.    O

where    O
the    O
Poisson    B-Calculation105802185
kernel    I-Calculation105802185
"    O
P    O
"    O
is    O
given    O
by    O

The    O
Carleson    O
condition    O
is    O
closely    O
related    O
to    O
the    O
boundedness    O
of    O
the    O
Poisson    B-Calculation105802185
operator    I-Calculation105802185
.    O

In    O
potential    O
theory    O
,    O
the    O
Poisson    B-Calculation105802185
kernel    I-Calculation105802185
is    O
an    O
integral    O
kernel    O
,    O
used    O
for    O
solving    O
the    O
two    O
-    O
dimensional    O
Laplace    O
equation    O
,    O
given    O
Dirichlet    O
boundary    O
conditions    O
on    O
the    O
unit    O
disc    O
.    O

This    O
result    O
also    O
follows    O
easily    O
using    O
Fourier    O
series    O
and    O
the    O
Poisson    B-Calculation105802185
integral    I-Calculation105802185
.    O

Let    O
"    O
w    O
"    O
be    O
the    O
harmonic    O
function    O
given    O
by    O
the    O
Poisson    B-Calculation105802185
integral    I-Calculation105802185
on    O

The    O
formula    O
follows    O
from    O
Poisson    B-Calculation105802185
integral    I-Calculation105802185
formula    I-Calculation105802185
applied    O
to    O
"    O
u    O
"    O
:    O

PAH    O
(    O
"para"-aminohippurate    B-Calculation105802185
)    O
is    O
freely    O
filtered    O
,    O
is    O
not    O
reabsorbed    O
,    O
and    O
is    O
secreted    O
within    O
the    O
nephron    O
.    O

When    O
using    O
a    O
compound    O
with    O
an    O
extraction    O
ratio    O
near    O
1    O
,    O
such    O
as    O
para-aminohippurate    B-Calculation105802185
(    O
PAH    O
)    O
,    O
eRPF    O
approximates    O
RPF    O
.    O

In    O
mathematics    O
,    O
in    O
the    O
field    O
of    O
p    O
-    O
adic    O
analysis    O
,    O
the    O
Volkenborn    B-Calculation105802185
integral    I-Calculation105802185
is    O
a    O
method    O
of    O
integration    O
for    O
p    O
-    O
adic    O
functions    O
.    O

Triiodothyronine    O
is    O
formed    O
,    O
when    O
diiodotyrosine    O
is    O
combined    O
with    O
monoiodotyrosine    B-Calculation105802185
(    O
in    O
the    O
colloid    O
of    O
the    O
thyroid    O
follicle    O
)    O
.    O

Monoiodotyrosine    B-Calculation105802185
is    O
a    O
precursor    O
of    O
thyroid    O
hormone    O
and    O
results    O
from    O
halogenation    O
of    O
tyrosine    O
at    O
the    O
meta    O
-    O
position    O
of    O
the    O
benzene    O
ring    O
.    O

Since    O
"    O
X    O
/    O
n    O
"    O
and    O
"    O
Y    O
/    O
n    O
"    O
are    O
asymptotically    O
normally    O
distributed    O
by    O
the    O
CLT    O
,    O
our    O
results    O
follow    O
by    O
application    O
of    O
the    O
delta    B-Calculation105802185
method    I-Calculation105802185
.    O

Each    O
ballot    O
can    O
,    O
therefore    O
,    O
be    O
viewed    O
as    O
a    O
small    O
"    O
delta    B-Calculation105802185
"    O
that    O
separates    O
two    O
groups    O
of    O
candidates    O
:    O
those    O
supported    O
and    O
those    O
that    O
are    O
not    O
.    O

An    O
admissible    O
heuristic    O
can    O
be    O
derived    O
from    O
a    O
relaxed    B-Calculation105802185

The    O
algorithm    O
is    O
based    O
around    O
creating    O
a    O
relaxation    B-Calculation105802185
for    O
nonlinear    O
functions    O
of    O
general    O
form    O
by    O
superposing    O
them    O
with    O
a    O
quadratic    O
of    O
sufficient    O
magnitude    O
,    O
called    O
α    O
,    O
such    O
that    O
the    O
resulting    O
superposition    O
is    O
enough    O
to    O
overcome    O
the    O
worst    O
-    O
case    O
scenario    O
of    O
non    O
-    O
convexity    O
of    O
the    O
original    O
function    O
.    O

1799    O
Gauss    O
finds    O
the    O
connection    O
of    O
the    O
length    O
of    O
a    O
lemniscate    O
and    O
a    O
case    O
of    O
the    O
arithmetic    O
-    O
geometric    O
mean    O
,    O
giving    O
a    O
numerical    O
method    O
for    O
a    O
complete    B-Calculation105802185
elliptic    I-Calculation105802185
integral    I-Calculation105802185
.    O

The    O
representation    O
implies    O
that    O
the    O
incomplete    B-Calculation105802185
elliptic    I-Calculation105802185
integral    I-Calculation105802185
Π    O
is    O
a    O
special    O
case    O
of    O
Lauricella    O
's    O
function    O
"    O
F""D    O
"    O
with    O
three    O
variables    O
:    O

The    O
connection    O
passes    O
through    O
hyperbolic    O
geometry    O
and    O
ergodic    O
theory    O
,    O
where    O
the    O
elliptic    B-Calculation105802185
integral    I-Calculation105802185
and    O
modular    O
forms    O
play    O
a    O
prominent    O
role    O
;    O
the    O
"    O
q    O
"-    O
series    O
themselves    O
are    O
closely    O
related    O
to    O
elliptic    O
integrals    O
.    O

Kevin    O
Kuns    O
(    O
2007    O
)    O
Calculation    O
of    O
Magnetic    O
Field    O
inside    O
Plasma    O
Chamber    O
,    O
uses    O
elliptic    B-Calculation105802185
integral    I-Calculation105802185
and    O
their    O
derivatives    O
to    O
compute    O
off    O
-    O
axis    O
fields    O
,    O
from    O
PBworks    O
.    O

Borwein    O
and    O
Zucker    O
have    O
found    O
that    O
can    O
be    O
expressed    O
algebraically    O
in    O
terms    O
of    O
,    O
,    O
,    O
,    O
and    O
where    O
is    O
a    O
complete    B-Calculation105802185
elliptic    I-Calculation105802185
integral    I-Calculation105802185
of    I-Calculation105802185
the    I-Calculation105802185
first    I-Calculation105802185
kind    I-Calculation105802185
.    O

where    O
"    O
K    O
"    O
and    O
"    O
E    O
"    O
denote    O
the    O
complete    B-Calculation105802185
elliptic    I-Calculation105802185
integrals    I-Calculation105802185
of    O
the    O
first    O
and    O
second    O
kind    O
respectively    O
.    O

Clause    O
19    O
defines    O
numerous    O
special    O
functions    O
,    O
including    O
the    O
gamma    O
function    O
,    O
Riemann    O
zeta    O
function    O
,    O
beta    O
function    O
,    O
exponential    B-Calculation105802185
integral    I-Calculation105802185
,    O
logarithmic    B-Calculation105802185
integral    I-Calculation105802185
,    O
sine    B-Calculation105802185
integral    I-Calculation105802185
,    O
Fresnel    B-Calculation105802185
integrals    I-Calculation105802185
,    O
error    O
function    O
,    O
incomplete    B-Calculation105802185
elliptic    I-Calculation105802185
integrals    I-Calculation105802185
,    O
hypergeometric    O
functions    O
,    O
Legendre    O
polynomials    O
,    O
spherical    O
harmonics    O
,    O
Hermite    O
polynomials    O
,    O
Laguerre    O
polynomials    O
,    O
Chebyshev    O
polynomials    O
,    O
Bessel    O
functions    O
,    O
Neumann    O
functions    O
,    O
Hankel    O
functions    O
and    O
Airy    O
functions    O
.    O

Also    O
of    O
interest    O
is    O
the    O
integration    O
of    O
differential    O
equations    O
in    O
Lexell    O
's    O
paper    O
"    O
On    O
reducing    O
integral    O
formulas    O
to    O
rectification    O
of    O
ellipses    O
and    O
hyperbolae    O
"    O
,    O
which    O
discusses    O
elliptic    B-Calculation105802185
integrals    I-Calculation105802185
and    O
their    O
classification    O
,    O
and    O
in    O
his    O
paper    O
"    O
Integrating    O
one    O
differential    O
formula    O
with    O
logarithms    O
and    O
circular    O
functions    O
"    O
,    O
which    O
was    O
reprinted    O
in    O
the    O
transactions    O
of    O
the    O
Swedish    O
Academy    O
of    O
Sciences    O
.    O

Abelian    O
integrals    O
are    O
natural    O
generalizations    O
of    O
elliptic    B-Calculation105802185
integral    I-Calculation105802185
,    O
which    O
arise    O
when    O

In    O
the    O
case    O
of    O
a    O
compact    O
Riemann    O
surface    O
of    O
genus    O
1    O
,    O
i.e.    O
an    O
elliptic    O
curve    O
,    O
such    O
functions    O
are    O
the    O
elliptic    B-Calculation105802185
integral    I-Calculation105802185
.    O

The    O
differentials    O
of    O
the    O
first    O
kind    O
,    O
when    O
integrated    O
along    O
paths    O
,    O
give    O
rise    O
to    O
integrals    O
that    O
generalise    O
the    O
elliptic    B-Calculation105802185
integral    I-Calculation105802185
to    O
all    O
curves    O
over    O
the    O
complex    O
numbers    O
.    O

In    O
the    O
early    O
19th    O
century    O
the    O
theory    O
of    O
elliptic    O
functions    O
succeeded    O
in    O
giving    O
a    O
basis    O
for    O
the    O
theory    O
of    O
elliptic    B-Calculation105802185
integral    I-Calculation105802185
,    O
and    O
this    O
left    O
open    O
an    O
obvious    O
avenue    O
of    O
research    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
isonocardicin    O
A    O
,    O
and    O
one    O
product    O
,    O
nocardicin    B-Calculation105802185
A    I-Calculation105802185

Aceglutamide    B-Calculation105802185

Other    O
medications    O
have    O
been    O
shown    O
to    O
be    O
useful    O
in    O
topical    O
treatment    O
of    O
refractory    O
ulcers    O
,    O
including    O
glycosaminoglycans    O
such    O
as    O
sodium    O
hyaluronate    O
and    O
chondroitin    O
sulfate    O
,    O
aminocaproic    O
acid    O
,    O
and    O
acetylcysteine    B-Calculation105802185
.    O

Treatment    O
includes    O
antibiotics    O
and    O
collagenase    O
inhibitors    O
such    O
as    O
acetylcysteine    B-Calculation105802185
and    O
homologous    O
blood    O
serum    O
.    O

Acetylcysteine    B-Calculation105802185
was    O
found    O
to    O
reduce    O
effectiveness    O
of    O
shogaol    O
's    O
apoptotic    O
properties    O
.    O

"N"-Acetylcysteine    B-Calculation105802185
(    O
NAC    O
)    O
is    O
a    O
precursor    O
to    O
glutathione    O
,    O
an    O
antioxidant    O
.    O

Outside    O
North    O
America    O
,    O
mesna    O
is    O
also    O
used    O
as    O
a    O
mucolytic    O
agent    O
,    O
working    O
in    O
the    O
same    O
way    O
as    O
acetylcysteine    B-Calculation105802185
;    O
it    O
is    O
sold    O
for    O
this    O
indication    O
as    O
Mistabron    O
and    O
Mistabronco    O
.    O

As    O
glutathione    O
depletion    O
has    O
been    O
shown    O
to    O
regulate    O
liver    O
toxification    O
,    O
administration    O
of    O
N-acetylcysteine    B-Calculation105802185
in    O
similar    O
doses    O
as    O
given    O
for    O
acetaminophen    O
toxicity    O
have    O
been    O
given    O
to    O
patients    O
.    O

Another    O
class    O
of    O
possible    O
pharmacological    O
treatments    O
are    O
glutamatergic    O
agents    O
such    O
as    O
n-acetyl    B-Calculation105802185
cysteine    I-Calculation105802185
(    O
NAC    O
)    O
.    O

In    O
addition    O
,    O
NAC    O
,    O
or    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
cysteine    O
(    O
acetylcysteine    B-Calculation105802185
)    O
,    O
has    O
been    O
shown    O
to    O
reduce    O
ROS    O
formation    O
associated    O
with    O
the    O
excessive    O
vibrations    O
induced    O
by    O
the    O
noise    O
exposure    O
.    O

Borderline    O
Substances    O
(    O
i.e.    O
Acetylcysteine    B-Calculation105802185
)    O

The    O
Rumack    O
-    O
Matthew    O
nomogram    O
,    O
also    O
known    O
as    O
Rumack    O
-    O
Matthews    O
nomogram    O
or    O
the    O
Acetaminophen    O
nomogram    O
is    O
an    O
acetaminophen    O
toxicity    O
nomogram    O
plotting    O
serum    O
concentration    O
of    O
acetaminophen    O
against    O
the    O
time    O
since    O
ingestion    O
in    O
an    O
attempt    O
to    O
prognosticate    O
possible    O
liver    O
toxicity    O
as    O
well    O
as    O
allowing    O
a    O
clinician    O
to    O
decide    O
whether    O
to    O
proceed    O
with    O
N-Acetylcysteine    B-Calculation105802185
(    O
NAC    O
)    O
treatment    O
or    O
not    O
.    O

Research    O
shows    O
that    O
nitrotyrosine    O
levels    O
can    O
be    O
reduced    O
by    O
N-acetyl    B-Calculation105802185
cysteine    I-Calculation105802185
,    O
which    O
is    O
a    O
precursor    O
to    O
glutathione    O
,    O
one    O
of    O
the    O
body    O
's    O
primary    O
endogenous    O
antioxidants    O
.    O

Furthermore    O
,    O
acetylcysteine    B-Calculation105802185
has    O
been    O
confirmed    O
,    O
in    O
a    O
recent    O
double    O
-    O
blind    O
placebo    O
-    O
controlled    O
trial    O
conducted    O
by    O
the    O
US    O
military    O
,    O
to    O
reduce    O
the    O
effects    O
of    O
blast    O
induced    O
mild    O
traumatic    O
brain    O
and    O
neurological    O
injury    O
in    O
soldiers    O
.    O

Penicillium    O
purpurescens    O
"    O
produces    O
hadacidin    B-Calculation105802185
.    O

Biotin    O
is    O
attached    O
to    O
these    O
carboxylase    O
enzymes    O
through    O
an    O
amino    O
acid    O
(    O
the    O
building    O
material    O
of    O
proteins    O
)    O
called    O
lysine    O
,    O
forming    O
a    O
complex    O
called    O
biocytin    B-Calculation105802185
.    O

:    O
N07CA04    O
Acetylleucine    B-Calculation105802185

Taylor    B-Calculation105802185
expansions    I-Calculation105802185
for    I-Calculation105802185
the    I-Calculation105802185
moments    I-Calculation105802185
of    I-Calculation105802185
functions    I-Calculation105802185
of    I-Calculation105802185
random    I-Calculation105802185
variables    I-Calculation105802185

Lymecycline    B-Calculation105802185
is    O
a    O
tetracycline    O
broad    O
-    O
spectrum    O
antibiotic    O
marketed    O
by    O
the    O
pharmaceutical    O
company    O
Galderma    O
.    O

In    O
more    O
recent    O
years    O
,    O
studies    O
have    O
suggested    O
the    O
use    O
of    O
urinary    O
benzylmercapturic    B-Calculation105802185
acid    I-Calculation105802185
as    O
the    O
best    O
marker    O
for    O
toluene    O
exposure    O
,    O
because    O
:    O
it    O
is    O
not    O
detected    O
in    O
non    O
-    O
exposed    O
subjects    O
;    O
it    O
is    O
more    O
sensitive    O
than    O
hippuric    B-Calculation105802185
acid    I-Calculation105802185
at    O
low    O
concentrations    O
;    O
it    O
is    O
not    O
affected    O
by    O
eating    O
or    O
drinking    O
;    O
it    O
can    O
detect    O
toluene    O
exposure    O
down    O
to    O
approximately    O
15    O
ppm    O
;    O
and    O
it    O
shows    O
a    O
better    O
quantitative    O
relationship    O
with    O
toluene    O
than    O
hippuric    B-Calculation105802185
acid    I-Calculation105802185
or    O
"    O
o    O
"-    O
cresol    O
.    O

It    O
is    O
made    O
from    O
a    O
combination    O
of    O
imipenem    O
and    O
cilastatin    B-Calculation105802185
.    O

It    O
is    O
a    O
broad    O
-    O
spectrum    O
beta    O
-    O
lactam    O
containing    O
equal    O
quantities    O
of    O
imipenem    O
and    O
cilastatin    B-Calculation105802185
.    O

This    O
observation    O
can    O
allow    O
one    O
to    O
sometimes    O
make    O
"    O
back    B-Calculation105802185
of    I-Calculation105802185
the    I-Calculation105802185
envelope    I-Calculation105802185
"    O
calculations    O
about    O
the    O
phenomenon    O
of    O
interest    O
,    O
and    O
therefore    O
be    O
able    O
to    O
more    O
efficiently    O
design    O
experiments    O
to    O
measure    O
it    O
,    O
or    O
to    O
judge    O
whether    O
it    O
is    O
important    O
,    O
etc    O
.    O

Wilkins    O
made    O
a    O
number    O
of    O
back-of-the-envelope    B-Calculation105802185
calculation    I-Calculation105802185
demonstrating    O
the    O
amount    O
of    O
energy    O
needed    O
would    O
be    O
impossible    O
given    O
the    O
state    O
of    O
the    O
art    O
in    O
electronics    O
.    O

;    O
back-of-the-envelope    B-Calculation105802185
calculation    I-Calculation105802185
:    O
An    O
informal    O
computation    O
omitting    O
much    O
rigor    O
without    O
sacrificing    O
correctness    O
.    O

In    O
patients    O
with    O
deficiency    O
of    O
transaldolase    O
,    O
there    O
's    O
an    O
accumulation    O
of    O
erythritol    O
(    O
from    O
erythrose    B-Calculation105802185
4-phosphate    I-Calculation105802185
)    O
,    O
D    O
-    O
arabitol    O
,    O
and    O
ribitol    O
.    O

This    O
cleavage    O
reaction    O
generates    O
the    O
unusual    O
aldose    O
sugar    O
erythrose-4-phosphate    B-Calculation105802185
.    O

Erythrose    B-Calculation105802185
4-phosphate    I-Calculation105802185
is    O
a    O
phosphate    O
of    O
the    O
simple    O
sugar    O
erythrose    O
.    O

In    O
the    O
Calvin    O
cycle    O
aldolase    O
also    O
catalyzes    O
the    O
production    O
of    O
sedoheptulose    O
1,7-bisphosphate    O
from    O
DHAP    O
and    O
erythrose    B-Calculation105802185
4-phosphate    I-Calculation105802185
.    O

His    O
works    O
solved    O
all    O
major    O
problems    O
of    O
the    O
Plane    O
Elasticity    O
Theory    O
opening    O
a    O
wide    O
class    O
of    O
domains    O
reducing    O
the    O
plane    O
problem    O
to    O
finite    O
systems    O
of    O
linear    O
algebraic    O
equations    O
c    B-Calculation105802185
singular    I-Calculation105802185
kernels    I-Calculation105802185
.    O

Singular    B-Calculation105802185
integrals    I-Calculation105802185

Singular    B-Calculation105802185
integral    I-Calculation105802185

In    O
its    O
general    O
nature    O
,    O
it    O
is    O
a    O
singular    B-Calculation105802185
integral    I-Calculation105802185
operator    I-Calculation105802185
,    O
defined    O
by    O
convolution    O
with    O
a    O
function    O
having    O
a    O
mathematical    O
singularity    O
at    O
the    O
origin    O
,    O
the    O
Newtonian    O
kernel    O
Γ    O
which    O
is    O
the    O
fundamental    O
solution    O
of    O
the    O
Laplace    O
equation    O
.    O

In    O
mathematics    O
,    O
the    O
Calderón    O
–    O
Zygmund    O
lemma    O
is    O
a    O
fundamental    O
result    O
in    O
Fourier    O
analysis    O
,    O
harmonic    O
analysis    O
,    O
and    O
singular    B-Calculation105802185
integral    I-Calculation105802185
.    O

Kirkwood    B-Calculation105802185
approximation    I-Calculation105802185

It    O
was    O
prepared    O
with    O
coffee    B-Calculation105802185
syrup    I-Calculation105802185
and    O
cold    O
water    O
.    O

The    O
Opera    O
is    O
a    O
rectangular    O
cake    O
composed    O
of    O
three    O
thin    O
layers    O
of    O
almond    O
sponge    O
cake    O
soaked    O
in    O
coffee    B-Calculation105802185
syrup    I-Calculation105802185
alternating    O
between    O
layers    O
of    O
coffee    O
butter    O
cream    O
and    O
chocolate    O
glaze    O
topped    O
with    O
ganache    O
.    O

He    O
was    O
addicted    O
to    O
coffee    B-Calculation105802185
milk    I-Calculation105802185
,    O
which    O
was    O
the    O
reason    O
why    O
he    O
was    O
n't    O
in    O
hibernation    O
himself    O
.    O

These    O
include    O
soy    O
-    O
based    O
formulas    O
,    O
hypoallergenic    O
formulas    O
based    O
on    O
partially    O
or    O
extensively    O
hydrolyzed    O
protein    O
,    O
and    O
free    O
amino    B-Calculation105802185
acid-based    I-Calculation105802185
formula    I-Calculation105802185
such    O
as    O
Neocate    O
,    O
EleCare    O
,    O
and    O
Puramino    O
.    O
'    O

"para"-Chlorophenylalanine    B-Calculation105802185
(    O
PCPA    O
)    O

"para"-Chlorophenylalanine    B-Calculation105802185
(    O
PCPA    O
)    O

:    O
Using    O
the    O
substitution    B-Calculation105802185
"    O
v    O
"    O
=    O
"    O
u"2/2    O
,    O
the    O
upper    O
bound    O
is    O
derived    O
as    O
follows    O
:    O

If    O
we    O
now    O
make    O
the    O
substitution    B-Calculation105802185
,    O
the    O
result    O
is    O
the    O
integral    O
of    O
a    O
rational    O
function    O
:    O

By    O
the    O
substitution    B-Calculation105802185
rule    I-Calculation105802185
of    O
integral    O
calculus    O
,    O
we    O
then    O
have    O

Integration    B-Calculation105802185
by    I-Calculation105802185
substitution    I-Calculation105802185
,    O
a    O
method    O
for    O
computing    O
integrals    O
,    O
by    O
using    O
a    O
change    O
of    O
variable    O

Integration    B-Calculation105802185
by    I-Calculation105802185
substitution    I-Calculation105802185

By    O
integration    B-Calculation105802185
by    I-Calculation105802185
substitution    I-Calculation105802185
,    O
one    O
can    O
show    O
that    O

for    O
all    O
positive    O
real    O
"    O
t    O
"    O
and    O
all    O
test    O
functions    O
φ.    O
The    O
additional    O
factor    O
of    O
"    O
t"−"n    O
"    O
is    O
needed    O
to    O
reproduce    O
the    O
usual    O
notion    O
of    O
homogeneity    O
for    O
locally    O
integrable    O
functions    O
,    O
and    O
comes    O
about    O
from    O
the    O
Jacobian    B-Calculation105802185
change    I-Calculation105802185
of    I-Calculation105802185
variables    I-Calculation105802185
.    O

Other    O
examples    O
of    O
monobactams    O
are    O
tigemonam    O
,    O
nocardicin    B-Calculation105802185
A    I-Calculation105802185
,    O
and    O
tabtoxin    B-Calculation105802185
.    O

An    O
example    O
of    O
such    O
a    O
methodology    O
is    O
Gibbs    O
ensemble    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
,    O
which    O
provides    O
a    O
direct    O
way    O
to    O
obtain    O
coexistence    O
properties    O
of    O
fluids    O
from    O
a    O
single    O
simulation    O
.    O

There    O
are    O
other    O
approximate    O
methods    O
for    O
marginalization    O
including    O
variational    O
methods    O
and    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
.    O

Since    O
weather    O
related    O
volume    O
risk    O
drivers    O
can    O
be    O
represented    O
in    O
the    O
form    O
of    O
historical    O
weather    O
records    O
over    O
many    O
years    O
,    O
a    O
Monte-Carlo    B-Calculation105802185
simulation    I-Calculation105802185
approach    O
is    O
often    O
used    O
.    O

His    O
contributions    O
focused    O
on    O
the    O
area    O
of    O
statistics    O
including    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
,    O
model    O
selection    O
,    O
and    O
genomic    O
analysis    O
.    O

Part    O
of    O
his    O
dissertation    O
derived    O
procedures    O
for    O
stochastically    O
simulating    O
high    O
-    O
energy    O
elementary    O
particle    O
reactions    O
using    O
digital    O
computers    O
,    O
and    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
would    O
play    O
a    O
major    O
role    O
in    O
his    O
later    O
work    O
.    O

Many    O
modern    O
microarray    O
analysis    O
techniques    O
involve    O
bootstrapping    O
(    O
statistics    O
)    O
,    O
machine    O
learning    O
or    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
methods    I-Calculation105802185
.    O

Riskdata    O
computes    O
risk    O
indicators    O
such    O
as    O
Value    O
-    O
at    O
-    O
Risk    O
(    O
historical    O
and    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
)    O
,    O
Greeks    O
,    O
tracking    O
error    O
,    O
volatility    O
,    O
stress    O
tests    O
,    O
liquidity    O
risk    O
for    O
cross    O
-    O
asset    O
portfolios    O
.    O

The    O
HuLK    O
VaR    O
(    O
previously    O
named    O
Shock    O
VaR    O
)    O
is    O
a    O
specific    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
VaR    O
methodology    O
developed    O
by    O
Riskdata    O
that    O
allows    O
avoiding    O
over    O
or    O
under    O
estimating    O
risk    O
across    O
market    O
crisis    O
.    O

The    O
ease    O
with    O
which    O
the    O
Plummer    O
sphere    O
can    O
be    O
realized    O
as    O
a    O
Monte-Carlo    B-Calculation105802185
model    I-Calculation105802185
has    O
made    O
it    O
a    O
favorite    O
choice    O
of    O
N    O
-    O
body    O
experimenters    O
,    O
in    O
spite    O
of    O
the    O
model    O
's    O
lack    O
of    O
realism    O
.    O

A    O
discussion    O
of    O
the    O
problem    O
of    O
pricing    O
Asian    O
options    O
with    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
is    O
given    O
in    O
a    O
paper    O
by    O
Kemna    O
and    O
Vorst    O
.    O

Numerical    O
lattice    O
QCD    O
calculations    O
using    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
can    O
be    O
extremely    O
computationally    O
intensive    O
,    O
requiring    O
the    O
use    O
of    O
the    O
largest    O
available    O
supercomputers    O
.    O

Lattice    O
QCD    O
predicts    O
that    O
confined    O
quarks    O
will    O
become    O
released    O
to    O
quark    O
-    O
gluon    O
plasma    O
around    O
energies    O
of    O
150    O
MeV.    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
are    O
free    O
from    O
the    O
sign    O
problem    O
when    O
applied    O
to    O
the    O
case    O
of    O
QCD    O
with    O
gauge    O
group    O
SU(2    O
)    O
(    O
QC2D    O
)    O
.    O

Monte-Carlo    B-Calculation105802185
is    O
a    O
method    O
to    O
pseudo    O
-    O
randomly    O
sample    O
a    O
large    O
space    O
of    O
variables    O
.    O

It    O
is    O
a    O
particular    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
that    O
numerically    O
computes    O
a    O
definite    O
integral    O
.    O

Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185

=    O
=    O
=    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
principles    I-Calculation105802185

The    O
control    O
variates    O
method    O
is    O
a    O
variance    O
reduction    O
technique    O
used    O
in    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
methods    I-Calculation105802185
.    O

#    O
a    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
,    O
in    O
which    O
an    O
approximation    O
to    O
the    O
distribution    O
function    O
for    O
is    O
established    O
numerically    O
by    O
making    O
random    O
draws    O
from    O
the    O
probability    O
distributions    O
for    O
the    O
input    O
quantities    O
,    O
and    O
evaluating    O
the    O
model    O
at    O
the    O
resulting    O
values    O
.    O

In    O
1977    O
P.    O
Boyle    O
,    O
University    O
of    O
Waterloo    O
,    O
proposed    O
using    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
(MC)    I-Calculation105802185
to    O
evaluate    O
options    O
.    O

Sinclair    O
’s    O
research    O
interests    O
include    O
the    O
design    O
and    O
analysis    O
of    O
randomized    O
algorithms    O
,    O
computational    O
applications    O
of    O
stochastic    O
processes    O
and    O
nonlinear    O
dynamical    O
systems    O
,    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
in    O
Statistical    O
Physics    O
,    O

The    O
dispersion    O
model    O
,    O
LODI    O
,    O
solves    O
the    O
3-D    O
advection    O
-    O
diffusion    O
equation    O
using    O
a    O
Lagrangian    O
stochastic    O
,    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
.    O

In    O
the    O
mid-1940s    O
,    O
the    O
RAND    O
Corporation    O
set    O
about    O
to    O
develop    O
a    O
large    O
table    O
of    O
random    O
numbers    O
for    O
use    O
with    O
the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
,    O
and    O
using    O
a    O
hardware    O
random    O
number    O
generator    O
produced    O
"    O
A    O
Million    O
Random    O
Digits    O
with    O
100,000    O
Normal    O
Deviates    O
"    O
.    O

Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
in    O
physics    O
and    O
computer    O
science    O
require    O
random    O
numbers    O
.    O

Elements    O
of    O
statistical    O
practice    O
that    O
depend    O
on    O
randomness    O
include    O
:    O
choosing    O
a    O
representative    O
sample    O
of    O
the    O
population    O
being    O
examined    O
,    O
disguising    O
the    O
protocol    O
of    O
a    O
study    O
from    O
a    O
participant    O
(    O
see    O
randomized    O
controlled    O
trial    O
)    O
and    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulation    O
.    O

The    O
company    O
’s    O
initial    O
product    O
was    O
a    O
software    O
algorithm    O
that    O
dramatically    O
reduced    O
the    O
time    O
required    O
for    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
pricing    O
of    O
exotic    O
financial    O
derivatives    O
and    O
structured    O
products    O
.    O

A    O
back    O
-    O
end    O
discrete    O
-    O
event    O
simulation    O
that    O
employs    O
the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
.    O

The    O
more    O
refined    O
analysis    O
of    O
reaction    O
(    O
4    O
)    O
was    O
carried    O
out    O
by    O
Bates    O
et    O
Morgan    O
.    O
who    O
found    O
that    O
the    O
Monte-Carlo    B-Calculation105802185
method    I-Calculation105802185
,    O
Flannery    O
's    O
equation    O
and    O
Langevin    O
's    O
theory    O
can    O
give    O
good    O
results    O
only    O
when    O
the    O
pressure    O
is    O
above    O
1    O
atm    O
.    O

Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185

At    O
this    O
level    O
of    O
performance    O
,    O
GnuGo    O
was    O
between    O
six    O
and    O
seven    O
stones    O
weaker    O
than    O
the    O
top    O
commercial    O
programs    O
on    O
good    O
hardware    O
as    O
of    O
early    O
2009    O
,    O
but    O
comparable    O
in    O
strength    O
to    O
the    O
strongest    O
programs    O
not    O
using    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
.    O

:    O
This    O
paper    O
records    O
the    O
first    O
use    O
of    O
the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
,    O
created    O
at    O
Los    O
Alamos    O
.    O

Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185

Although    O
there    O
is    O
no    O
simple    O
,    O
universal    O
rule    O
stating    O
how    O
large    O
the    O
sample    O
size    O
must    O
be    O
to    O
use    O
a    O
"    O
Z    O
"-    O
test    O
,    O
simulation    B-Calculation105802185
can    O
give    O
a    O
good    O
idea    O
as    O
to    O
whether    O
a    O
"    O
Z    O
"-    O
test    O
is    O
appropriate    O
in    O
a    O
given    O
situation    O
.    O

Some    O
evidence    O
for    O
this    O
can    O
be    O
had    O
by    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulation    I-Calculation105802185
.    O

These    O
are    O
used    O
to    O
determine    O
dynamical    O
pathways    O
between    O
different    O
protein    O
conformations    O
using    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
.    O

The    O
diverse    O
flavor    O
of    O
quantum    O
Monte    O
Carlo    O
approaches    O
all    O
share    O
the    O
common    O
use    O
of    O
the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
to    O
handle    O
the    O
multi    O
-    O
dimensional    O
integrals    O
that    O
arise    O
in    O
the    O
different    O
formulations    O
of    O
the    O
many    O
-    O
body    O
problem    O
.    O

Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185

Hypotheses    O
are    O
typically    O
sampled    O
using    O
a    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
sampling    I-Calculation105802185
technique    O
such    O
as    O
MCMC    O
.    O

Ulam    O
design    O
of    O
thermonuclear    O
weapons    O
,    O
discovered    O
the    O
concept    O
of    O
cellular    O
automaton    O
,    O
invented    O
the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
methods    I-Calculation105802185
of    O
computation    O
,    O
and    O
suggested    O
nuclear    O
pulse    O
propulsion    O
.    O

In    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
,    O
an    O
initial    O
configuration    O
is    O
refined    O
by    O
taking    O
random    O
steps    O
which    O
are    O
accepted    O
or    O
rejected    O
based    O
on    O
their    O
induced    O
improvement    O
in    O
score    O
(    O
see    O
the    O
Metropolis    O
criterion    O
)    O
,    O
until    O
a    O
certain    O
number    O
of    O
steps    O
have    O
been    O
tried    O
.    O

The    O
fundamental    O
drawback    O
associated    O
with    O
the    O
GERT    O
technique    O
is    O
the    O
complex    O
programme    O
(    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulation    I-Calculation105802185
)    O
required    O
to    O
model    O
the    O
GERT    O
system    O
.    O

Alternatively    O
,    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
methods    I-Calculation105802185
may    O
be    O
used    O
,    O
in    O
which    O
random    O
sample    O
points    O
are    O
generated    O
according    O
to    O
some    O
fixed    O
underlying    O
probability    O
distribution    O
,    O
assigned    O
to    O
the    O
closest    O
site    O
,    O
and    O
averaged    O
to    O
approximate    O
the    O
centroid    O
for    O
each    O
site    O
.    O

The    O
advent    O
of    O
computerized    O
resampling    O
methods    O
,    O
such    O
as    O
bootstrapping    O
and    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulation    I-Calculation105802185
,    O
has    O
given    O
rise    O
to    O
many    O
techniques    O
in    O
the    O
latter    O
category    O
.    O

The    O
Ziff    O
–    O
Gulari    O
–    O
Barshad    O
(    O
ZGB    O
)    O
model    O
is    O
a    O
simple    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
for    O
catalytic    O
reactions    O
of    O
oxidation    O
of    O
carbon    O
monoxide    O
to    O
carbon    O
dioxide    O
on    O
a    O
surface    O
using    O
Monte-Carlo    B-Calculation105802185
methods    I-Calculation105802185
which    O
captures    O
correctly    O
the    O
essential    O
dynamics    O
:    O
the    O
phase    O
transition    O
between    O
two    O
poisoned    O
states    O
(    O
either    O
CO2-    O
or    O
O    O
-    O
poisoned    O
)    O
and    O
a    O
steady    O
-    O
state    O
in    O
between    O
.    O

solid    O
interaction    O
both    O
experimentally    O
,    O
theoretically    O
and    O
using    O
molecular    O
dynamics    O
and    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulations    I-Calculation105802185
.    O

Depending    O
on    O
their    O
sophistication    O
,    O
they    O
may    O
be    O
stochastic    O
(    O
often    O
incorporating    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulation    I-Calculation105802185
)    O
or    O
deterministic    O
.    O

In    O
order    O
to    O
assess    O
the    O
influence    O
of    O
real    O
-    O
world    O
uncertainties    O
and    O
tolerances    O
on    O
a    O
given    O
design    O
,    O
Optimus    O
contains    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
Simulation    I-Calculation105802185
as    O
well    O
as    O
a    O
First    O
-    O
Order    O
Second    O
Moment    O
method    O
to    O
estimate    O
and    O
improve    O
the    O
robustness    O
of    O
a    O
design    O
.    O

:    O
RVNS    O
is    O
akin    O
to    O
a    O
Monte-Carlo    B-Calculation105802185
method    I-Calculation105802185
,    O
but    O
is    O
more    O
systematic    O
.    O

Fogaras    O
and    O
Racz    O
suggested    O
speeding    O
up    O
SimRank    O
computation    O
through    O
probabilistic    O
computation    O
using    O
the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
.    O

This    O
paper    O
,    O
an    O
experiment    O
on    O
the    O
Buffon    O
's    O
needle    O
problem    O
,    O
is    O
a    O
very    O
early    O
documented    O
use    O
of    O
random    O
sampling    O
(    O
which    O
Nicholas    O
Metropolis    O
would    O
name    O
the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
during    O
the    O
Manhattan    O
Project    O
of    O
World    O
War    O
II    O
)    O
in    O
scientific    O
inquiry    O
.    O

Probabilistic    O
models    O
are    O
based    O
on    O
the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    O
where    O
distributions    O
of    O
data    O
from    O
various    O
sources    O
are    O
randomly    O
sampled    O
from    O
to    O
calculate    O
percentile    O
statistics    O
.    O

It    O
has    O
been    O
shown    O
that    O
subset    O
simulation    O
is    O
more    O
efficient    O
than    O
traditional    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulation    I-Calculation105802185
,    O
but    O
less    O
efficient    O
than    O
Line    O
Sampling    O
,    O
when    O
applied    O
to    O
a    O
fracture    O
mechanics    O
test    O
problem    O
.    O

Using    O
direct    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
one    O
can    O
generate    O
i.i.d    O
.    O

Although    O
when    O
designing    O
the    O
SAM    O
missile    O
equipped    O
Mauler    O
in    O
the    O
late    O
1950s    O
,    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulations    I-Calculation105802185
on    O
the    O
IBM    O
650    O
were    O
conducted    O
which    O
influenced    O
the    O
decision    O
to    O
use    O
a    O
blast    O
-    O
fragmentation    O
warhead    O
,    O
as    O
a    O
continuous    O
-    O
rod    O
warhead    O
was    O
deemed    O
likely    O
to    O
be    O
less    O
effective    O
.    O

interfacing    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
event    O
generators    O
.    O

Given    O
a    O
potential    O
energy    O
function    O
,    O
the    O
radial    O
distribution    O
function    O
can    O
be    O
computed    O
either    O
via    O
computer    O
simulation    O
methods    O
like    O
the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
,    O
or    O
via    O
the    O
Ornstein    O
-    O
Zernike    O
equation    O
,    O
using    O
approximative    O
closure    O
relations    O
like    O
the    O
Percus    O
-    O
Yevick    O
approximation    O
or    O
the    O
Hypernetted    O
Chain    O
Theory    O
.    O

Monte    O
Carlo    O
molecular    O
modeling    O
is    O
the    O
application    O
of    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
to    O
molecular    O
problems    O
.    O

Frank    O
Dellaert    O
holds    O
interests    O
in    O
the    O
areas    O
of    O
robotics    O
and    O
computer    O
vision    O
,    O
including    O
Bayesian    O
inference    O
and    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
approximations    I-Calculation105802185
and    O
how    O
to    O
attain    O
efficiency    O
with    O
approximation    O
methods    O
.    O

Biochemical    O
and    O
Organic    O
Simulation    O
System    O
(    O
BOSS    O
)    O
is    O
a    O
general    O
-    O
purpose    O
molecular    O
modeling    O
program    O
that    O
performs    O
molecular    O
mechanics    O
calculations    O
,    O
Metropolis    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
statistical    O
mechanics    O
simulations    O
,    O
and    O
semiempirical    O
Austin    O
Model    O
1    O
(    O
AM1    O
)    O
,    O
PM3    O
,    O
and    O
PDDG    O
/    O
PM3    O
quantum    O
mechanics    O
calculations    O
.    O

At    O
the    O
core    O
of    O
a    O
radiative    O
transfer    O
model    O
lies    O
the    O
radiative    O
transfer    O
equation    O
that    O
is    O
numerically    O
solved    O
using    O
a    O
solver    O
such    O
as    O
a    O
discrete    O
ordinate    O
method    O
or    O
a    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
.    O

Nanoscale    O
:    O
semi    O
-    O
empirical    O
atomistic    O
methods    O
are    O
used    O
such    O
as    O
Lennard    O
-    O
Jones    O
,    O
Brenner    O
potentials    O
,    O
embedded    O
atom    O
method    O
(    O
EAM    O
)    O
potentials    O
,    O
and    O
modified    O
embedded    O
atom    O
potentials    O
(    O
MEAM    O
)    O
in    O
molecular    O
dynamics    O
(    O
MD    O
)    O
,    O
molecular    O
statics    O
(    O
MS    O
)    O
,    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
(    O
MC    O
)    O
,    O
and    O
kinetic    O
Monte    O
Carlo    O
(    O
KMC    O
)    O
formulations    O
.    O

The    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
is    O
the    O
most    O
common    O
form    O
of    O
a    O
mathematical    O
model    O
that    O
is    O
applied    O
to    O
predict    O
long    O
-    O
term    O
investment    O
behavior    O
for    O
a    O
client    O
's    O
retirement    O
planning    O
.    O

Once    O
events    O
and    O
event    O
chains    O
are    O
defined    O
,    O
quantitative    O
analysis    O
using    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulation    I-Calculation105802185
can    O
be    O
performed    O
to    O
quantify    O
the    O
cumulative    O
effect    O
of    O
the    O
events    O
.    O

Monte    B-Calculation105802185
Carlo    I-Calculation105802185
simulation    I-Calculation105802185

Massively    O
Parallel    O
Monte    O
Carlo    O
(    O
MPMC    O
)    O
is    O
an    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
package    O
primarily    O
designed    O
to    O
simulate    O
liquids    O
,    O
molecular    O
interfaces    O
,    O
and    O
functionalized    O
nanoscale    O
materials    O
.    O

BTE    O
can    O
be    O
numerically    O
solved    O
with    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
,    O
etc    O
.    O

the    O
Monte    B-Calculation105802185
Carlo    I-Calculation105802185
method    I-Calculation105802185
(    O
including    O
Latin    O
hypercubes    O
)    O
;    O

Dextrothyroxine    B-Calculation105802185
(    O
trade    O
name    O
Choloxin    B-Calculation105802185
)    O
saw    O
research    O
as    O
a    O
cholesterol    O
-    O
lowering    O
drug    O
but    O
was    O
pulled    O
due    O
to    O
cardiac    O
side    O
-    O
effects    O
.    O

Improper    B-Calculation105802185
integral    I-Calculation105802185

If    O
improper    B-Calculation105802185
Riemann    O
–    O
Stieltjes    O
integrals    O
are    O
allowed    O
,    O
the    O
Lebesgue    O
integral    O
is    O
not    O
strictly    O
more    O
general    O
than    O
the    O
Riemann    O
–    O
Stieltjes    O
integral    O
.    O

The    O
improper    B-Calculation105802185
integral    I-Calculation105802185
has    O
unbounded    O
intervals    O
for    O
both    O
domain    O
and    O
range    O
.    O

converges    O
to    O
a    O
real    O
number    O
if    O
and    O
only    O
if    O
the    O
improper    B-Calculation105802185
integral    I-Calculation105802185

A    O
semi    O
-    O
infinite    O
integral    O
is    O
an    O
improper    B-Calculation105802185
integral    I-Calculation105802185
over    O
a    O
semi    O
-    O
infinite    O
interval    O
.    O

The    O
Fresnel    B-Calculation105802185
integrals    I-Calculation105802185
,    O
still    O
used    O
to    O
calculate    O
wave    O
patterns    O
,    O
silence    O
skeptics    O
who    O
had    O
backed    O
the    O
particle    O
theory    O
of    O
Isaac    O
Newton    O
.    O

Clause    O
19    O
defines    O
numerous    O
special    O
functions    O
,    O
including    O
the    O
gamma    O
function    O
,    O
Riemann    O
zeta    O
function    O
,    O
beta    O
function    O
,    O
exponential    B-Calculation105802185
integral    I-Calculation105802185
,    O
logarithmic    B-Calculation105802185
integral    I-Calculation105802185
,    O
sine    B-Calculation105802185
integral    I-Calculation105802185
,    O
Fresnel    B-Calculation105802185
integrals    I-Calculation105802185
,    O
error    O
function    O
,    O
incomplete    B-Calculation105802185
elliptic    I-Calculation105802185
integrals    I-Calculation105802185
,    O
hypergeometric    O
functions    O
,    O
Legendre    O
polynomials    O
,    O
spherical    O
harmonics    O
,    O
Hermite    O
polynomials    O
,    O
Laguerre    O
polynomials    O
,    O
Chebyshev    O
polynomials    O
,    O
Bessel    O
functions    O
,    O
Neumann    O
functions    O
,    O
Hankel    O
functions    O
and    O
Airy    O
functions    O
.    O

A    O
typical    O
conditionally    O
convergent    O
integral    O
is    O
that    O
on    O
the    O
non    O
-    O
negative    O
real    O
axis    O
of    O
(    O
see    O
Fresnel    B-Calculation105802185
integral    I-Calculation105802185
)    O
.    O

The    O
Born–Huang    B-Calculation105802185
approximation    I-Calculation105802185
is    O
partially    O
named    O
after    O
him    O
.    O

Alpha    B-Calculation105802185
beta    I-Calculation105802185
filter    I-Calculation105802185

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
alpha-D-mannose    B-Calculation105802185
1-phosphate    I-Calculation105802185
,    O
and    O
one    O
product    O
,    O
D-mannose    B-Calculation105802185
6-phosphate    I-Calculation105802185
.    O

GlcNAc-1-phosphotransferase    O
catalyzes    O
the    O
N    O
-    O
linked    O
glycosylation    O
of    O
asparagine    O
residues    O
with    O
a    O
molecule    O
called    O
mannose-6-phosphate    B-Calculation105802185
(    O
M6P    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D    O
-    O
mannose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D-mannose    B-Calculation105802185
6-phosphate    I-Calculation105802185
.    O

The    O
precursor    O
to    O
the    O
lachrymatory    O
compound    O
,    O
(    O
RS    O
,    O
RC)-("E")-"S"-(1-butenyl    O
)    O
cysteine    O
"    O
S    O
"-    O
oxide    O
(    O
alliin    B-Calculation105802185
)    O
,    O
was    O
isolated    O
from    O
homogenates    O
of    O
"    O
A.    O
siculum    O
"    O
,    O
and    O
a    O
closely    O
related    O
species    O
,    O
"    O
Allium    O
tripedale    O
"    O
,    O
and    O
fully    O
characterized    O
.    O

Cysteine    O
sulphoxides    O
are    O
also    O
largely    O
responsible    O
for    O
the    O
flavour    O
and    O
spicy    O
taste    O
of    O
these    O
species    O
,    O
predominantly    O
the    O
isomeric    O
cysteine    O
derivatives    O
alliin    B-Calculation105802185
and    O
isoalliin    O
.    O

Propagation    B-Calculation105802185
of    I-Calculation105802185
uncertainty    I-Calculation105802185

A    O
related    O
practice    O
is    O
uncertainty    O
analysis    O
,    O
which    O
has    O
a    O
greater    O
focus    O
on    O
uncertainty    O
quantification    O
and    O
propagation    B-Calculation105802185
of    I-Calculation105802185
uncertainty    I-Calculation105802185
;    O
ideally    O
,    O
uncertainty    O
and    O
sensitivity    O
analysis    O
should    O
be    O
run    O
in    O
tandem    O
.    O

The    O
phase    O
detector    O
will    O
see    O
variations    O
in    O
frequency    O
as    O
measured    O
phase    O
noise    O
,    O
which    O
will    O
be    O
an    O
uncertainty    B-Calculation105802185
that    I-Calculation105802185
propagates    I-Calculation105802185
into    O
the    O
calculated    O
location    O
.    O

#    O
significance    O
of    O
the    O
breakpoint    O
(    O
BP    O
)    O
by    O
expressing    O
BP    O
as    O
a    O
function    O
of    O
"    O
regression    O
coefficients    O
"    O
A1    O
and    O
A2    O
and    O
the    O
means    O
Y1    O
and    O
Y2    O
of    O
the    O
y    O
-    O
data    O
and    O
the    O
means    O
X1    O
and    O
X2    O
of    O
the    O
x    O
data    O
(    O
left    O
and    O
right    O
of    O
BP    O
)    O
,    O
using    O
the    O
laws    O
of    O
propagation    B-Calculation105802185
of    I-Calculation105802185
errors    I-Calculation105802185
in    O
additions    O
and    O
multiplications    O
to    O
compute    O
the    O
standard    O
error    O
(    O
SE    O
)    O
of    O
BP    O
,    O
and    O
applying    O
Student    O
's    O
t    O
-    O
test    O

It    O
can    O
be    O
used    O
to    O
propagate    B-Calculation105802185
uncertainties    I-Calculation105802185
in    O
the    O
situation    O
where    O
errors    O
are    O
represented    O
by    O
intervals    O
.    O

Propagation    B-Calculation105802185
of    I-Calculation105802185
uncertainty    I-Calculation105802185

propagation    B-Calculation105802185
of    I-Calculation105802185
error    I-Calculation105802185
;    O

Citiolone    B-Calculation105802185
is    O
a    O
drug    O
used    O
in    O
liver    O
therapy    O
.    O

Borwein    B-Calculation105802185
integral    I-Calculation105802185

In    O
the    O
first    O
step    O
of    O
galactose    O
metabolism    O
,    O
galactose    O
is    O
converted    O
to    O
galactose-1-phosphate    B-Calculation105802185
(    O
Gal-1-P    O
)    O
by    O
the    O
enzyme    O
galactokinase    O
.    O

Galactokinase    O
then    O
phosphorylates    O
α-D    O
-    O
galactose    O
at    O
the    O
1    O
'    O
hydroxyl    O
group    O
,    O
yielding    O
galactose-1-phosphate    B-Calculation105802185
.    O

"    O
N"("z    O
"    O
)    O
=    O
−    O
"    O
E"("z    O
"    O
)    O
is    O
called    O
the    O
Newtonian    B-Calculation105802185
potential    I-Calculation105802185
in    O
the    O
plane    O
.    O

The    O
single    B-Calculation105802185
layer    I-Calculation105802185
potential    I-Calculation105802185
with    O
moment    O
φ    O
in    O
C(∂Ω    O
)    O
is    O
defined    O
on    O
C    O
as    O

where    O
"    O
N    O
"    O
is    O
the    O
Newtonian    B-Calculation105802185
potential    I-Calculation105802185

Specific    O
results    O
which    O
have    O
been    O
worked    O
out    O
by    O
various    O
techniques    O
are    O
collected    O
in    O
the    O
list    B-Calculation105802185
of    I-Calculation105802185
integrals    I-Calculation105802185
.    O

Extensive    O
tables    B-Calculation105802185
of    I-Calculation105802185
integrals    I-Calculation105802185
have    O
been    O
compiled    O
and    O
published    O
over    O
the    O
years    O
for    O
this    O
purpose    O
.    O

Lists    B-Calculation105802185
of    I-Calculation105802185
integrals    I-Calculation105802185
–    O
integrals    O
of    O
the    O
most    O
common    O
functions    O

Lists    B-Calculation105802185
of    I-Calculation105802185
integrals    I-Calculation105802185

Conjugation    O
with    O
glycine    O
forms    O
salicyluric    B-Calculation105802185
acid    I-Calculation105802185
,    O
and    O
with    O
glucuronic    O
acid    O
to    O
form    O
two    O
different    O
glucuronide    O
esters    O
.    O

Tetrazolylglycine    B-Calculation105802185
(    O
Tet-Gly    B-Calculation105802185
,    O
LY-285,265    B-Calculation105802185
)    O
is    O
a    O
potent    O
and    O
selective    O
NMDA    O
receptor    O
agonist    O
,    O
stimulating    O
the    O
NMDA    O
receptor    O
with    O
higher    O
potency    O
than    O
either    O
glutamate    O
or    O
NMDA    B-Calculation105802185
.    O

At    O
this    O
time    O
,    O
the    O
work    O
of    O
Cavalieri    O
with    O
his    O
method    O
of    O
Indivisibles    O
,    O
and    O
work    O
by    O
Fermat    O
,    O
began    O
to    O
lay    O
the    O
foundations    O
of    O
modern    O
calculus    O
,    O
with    O
Cavalieri    O
computing    O
the    O
integrals    O
of    O
up    O
to    O
degree    O
in    O
Cavalieri's    B-Calculation105802185
quadrature    I-Calculation105802185
formula    I-Calculation105802185
.    O

The    O
other    O
cases    O
are    O
given    O
by    O
Cavalieri's    B-Calculation105802185
quadrature    I-Calculation105802185
formula    I-Calculation105802185
.    O

Ombrabulin    B-Calculation105802185
was    O
an    O
experimental    O
drug    O
candidate    O
discovered    O
by    O
Ajinomoto    O
and    O
further    O
developed    O
by    O
Sanofi    O
-    O
Aventis    O
.    O

Reverse    B-Calculation105802185
T3    I-Calculation105802185
levels    O
are    O
generally    O
increased    O
signifying    O
inhibition    O
of    O
normal    O
type    O
1    O
deiodinase    O
or    O
reduced    O
clearance    O
of    O
reverse    O
T3    O
.    O

"    O
Inactivation    O
"    O
of    O
thyroid    O
hormones    O
occurs    O
by    O
removal    O
of    O
an    O
iodine    O
atom    O
on    O
the    O
inner    O
ring    O
,    O
which    O
converts    O
thyroxine    O
to    O
the    O
inactive    O
reverse    B-Calculation105802185
triiodothyronine    I-Calculation105802185
(    O
rT3    O
)    O
,    O
or    O
which    O
converts    O
the    O
active    O
triiodothyronine    O
to    O
diiodothyronine    O
(    O
T2    O
)    O
.    O

Portage    O
is    O
a    O
package    O
management    O
system    O
originally    O
created    O
for    O
and    O
used    O
by    O
Gentoo    O
Linux    O
and    O
also    O
by    O
Chrome    O
OS    O
,    O
Sabayon    B-Calculation105802185
,    O
and    O
Funtoo    O
Linux    O
among    O
others    O
.    O

SabayonLinux    B-Calculation105802185

Sabayon    B-Calculation105802185
Linux    I-Calculation105802185

Opines    B-Calculation105802185

A    O
naturally    O
occurring    O
soil    O
bacterium    O
"    O
Agrobacterium    O
rhizogenes    O
"    O
that    O
contains    O
root    O
-    O
inducing    O
plasmids    O
(    O
also    O
called    O
Ri    O
plasmids    O
)    O
can    O
infect    O
plant    O
roots    O
and    O
cause    O
them    O
to    O
produce    O
a    O
food    O
source    O
for    O
the    O
bacterium    O
,    O
opines    B-Calculation105802185
,    O
and    O
to    O
grow    O
abnormally    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    O
and    O
alpha-D-mannose    B-Calculation105802185
1-phosphate    I-Calculation105802185
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
GDP    O
-    O
mannose    O
.    O

Diiodotyrosine    B-Calculation105802185
(    O
DIT    O
)    O
is    O
a    O
precursor    O
in    O
the    O
production    O
of    O
thyroid    O
hormone    O
,    O
and    O
results    O
from    O
iodization    O
of    O
monoiodotyrosine    B-Calculation105802185
at    O
the    O
other    O
meta-    O
position    O
on    O
the    O
phenol    O
ring    O
.    O

One    O
unit    O
can    O
combine    O
with    O
diiodotyrosine    B-Calculation105802185
to    O
form    O
triiodothyronine    O
,    O
as    O
occurs    O
in    O
the    O
colloid    O
of    O
the    O
thyroid    O
follicle    O
.    O

As    O
an    O
undergraduate    O
he    O
specialized    O
in    O
the    O
development    O
of    O
geometric    O
methods    O
for    O
solving    O
calculus    O
problems    O
by    O
a    O
visual    O
approach    O
that    O
makes    O
no    O
use    O
of    O
formulas    O
,    O
which    O
he    O
later    O
developed    O
into    O
his    O
system    O
of    O
visual    B-Calculation105802185
calculus    I-Calculation105802185
.    O

FireballISO    B-Calculation105802185
–    O
VMware    O
virtual    O
machine    O
that    O
generates    O
a    O
customized    O
security    O
-    O
hardened    O
IPv4    O
and    O
IPv6    O
firewall    O
live    O
CD    O
.    O

Nitrosoproline    B-Calculation105802185
is    O
a    O
nitroso    O
derivative    O
of    O
the    O
amino    O
acid    O
proline    O
.    O

Tetrazolylglycine    B-Calculation105802185
(    O
Tet-Gly    B-Calculation105802185
,    O
LY-285,265    B-Calculation105802185
)    O
is    O
a    O
potent    O
and    O
selective    O
NMDA    O
receptor    O
agonist    O
,    O
stimulating    O
the    O
NMDA    O
receptor    O
with    O
higher    O
potency    O
than    O
either    O
glutamate    O
or    O
NMDA    B-Calculation105802185
.    O

Memantine    O
is    O
a    O
NMDA    B-Calculation105802185
receptor    O
antagonist    O
and    O
is    O
used    O
to    O
treat    O
patients    O
with    O
moderate    O
to    O
severe    O
Alzheimer    O
's    O
disease    O
,    O
but    O
is    O
also    O
used    O
as    O
a    O
neuroenhancement    O
drug    O
.    O

Several    O
adverse    O
biological    O
events    O
contribute    O
to    O
this    O
secondary    O
deterioration    O
,    O
including    O
:    O
release    O
of    O
excitatory    O
amino    O
acids    O
which    O
activate    O
N-methyl-D-aspartate    B-Calculation105802185
(    O
NMDA    O
)    O
and    O
amino-3-hydroxy-5-methyl-4-isoxazolepropionate    O
(    O
AMPA    O
)    O
receptors    O
on    O
neurons    O
(    O
30,37    O
)    O
and    O
oligodendroglial    O
precursors    O
,    O
accumulation    O
of    O
excitatory    O
neurotransmitters    O
,    O
generation    O
of    O
reactive    O
oxygen    O
radicals    O
,    O
intracellular    O
calcium    O
accumulation    O
and    O
mitochondrial    O
dysfunction    O
.    O

In    O
dendritic    O
spines    O
,    O
SK    O
channels    O
are    O
directly    O
coupled    O
to    O
NMDA    B-Calculation105802185
receptors    O
.    O

LTP    O
is    O
dependent    O
on    O
the    O
activity    O
of    O
NMDA    O
receptors    O
in    O
the    O
brain    O
and    O
it    O
has    O
been    O
shown    O
that    O
NMDA    B-Calculation105802185
activity    O
influences    O
acetylation    O
.    O

Tolerance    O
results    O
in    O
a    O
desensitization    O
of    O
GABA    O
receptors    O
and    O
an    O
increased    O
sensitization    O
of    O
the    O
excitatory    O
neurotransmitter    O
system    O
,    O
glutamate    O
such    O
as    O
NMDA    B-Calculation105802185
glutamate    O
receptors    O
.    O

Homocysteic    O
acid    O
is    O
a    O
sulfur    O
-    O
containing    O
glutamic    O
acid    O
analog    O
and    O
a    O
potent    O
NMDA    B-Calculation105802185
receptor    O
agonist    O
.    O

Toxicity    O
may    O
also    O
result    O
from    O
the    O
pharmacological    O
properties    O
of    O
the    O
drug    O
;    O
excess    O
NMDA    B-Calculation105802185
antagonism    O
can    O
completely    O
block    O
calcium    O
influx    O
into    O
neurons    O
and    O
provoke    O
cell    O
death    O
through    O
apoptosis    O
,    O
although    O
this    O
is    O
more    O
likely    O
to    O
be    O
a    O
long    O
-    O
term    O
result    O
of    O
chronic    O
solvent    O
abuse    O
than    O
a    O
consequence    O
of    O
short    O
-    O
term    O
use    O
.    O

During    O
postdoctoral    O
studies    O
at    O
the    O
Australian    O
National    O
University    O
with    O
David    O
Curtis    O
,    O
he    O
helped    O
establish    O
the    O
role    O
of    O
glutamate    O
as    O
a    O
central    O
neurotransmitter    O
and    O
characterised    O
its    O
actions    O
between    O
AMPA    O
,    O
N-Methyl-D-aspartic    B-Calculation105802185
acid    I-Calculation105802185
(NMDA)    I-Calculation105802185
and    O
kainate    O
receptor    O
subtypes    O
.    O

Excitotoxins    O
like    O
NMDA    B-Calculation105802185
and    O
kainic    O
acid    O
which    O
bind    O
to    O
these    O
receptors    O
,    O
as    O
well    O
as    O
pathologically    O
high    O
levels    O
of    O
glutamate    O
,    O
can    O
cause    O
excitotoxicity    O
by    O
allowing    O
high    O
levels    O
of    O
calcium    O
ions    O
(    O
Ca2    O
+    O
)    O
to    O
enter    O
the    O
cell    O
.    O

Following    O
research    O
,    O
excitotoxicity    O
appears    O
to    O
be    O
the    O
likely    O
mode    O
of    O
action    O
for    O
BMAA    O
which    O
acts    O
as    O
a    O
glutamate    O
agonist    O
,    O
activating    O
AMPA    O
and    O
NMDA    B-Calculation105802185
receptors    O
and    O
causing    O
damage    O
to    O
cells    O
even    O
at    O
relatively    O
low    O
concentrations    O
of    O
10    O
μM.    O
The    O
subsequent    O
uncontrolled    O
influx    O
of    O
Ca2    O
+    O
then    O
leads    O
to    O
the    O
pathophysiology    O
described    O
above    O
.    O

Propiram    O
exhibits    O
weak    O
opioid    O
antagonist    O
activity    O
on    O
the    O
mu    O
receptor    O
—    O
quite    O
a    O
bit    O
weaker    O
than    O
its    O
agonist    O
effects    O
—    O
and    O
the    O
effect    O
on    O
kappa    O
and    O
delta    O
opioid    O
,    O
sigma    O
receptors    O
,    O
or    O
the    O
NMDA    B-Calculation105802185
system    O
are    O
not    O
well    O
understood    O
.    O

Dextromethorphan    O
has    O
been    O
noted    O
to    O
slow    O
the    O
development    O
of    O
tolerance    O
to    O
opioids    O
and    O
exert    O
additional    O
analgesia    O
by    O
acting    O
upon    O
the    O
NMDA    B-Calculation105802185
receptors    O
;    O
some    O
analgesics    O
such    O
as    O
methadone    O
and    O
ketobemidone    O
and    O
perhaps    O
piritramide    O
have    O
intrinsic    O
NMDA    O
action    O
.    O

blocking    O
N    O
-    O
methyl    O
-    O
D    O
-    O
aspartate    O
(    O
NMDA    B-Calculation105802185
)    O
glutamate    O
receptors    O
,    O
an    O
excitatory    O
neurotransmitter    O
of    O
the    O
central    O
nervous    O
system    O
.    O

If    O
"    O
U    O
"    O
is    O
a    O
simply    O
-    O
connected    O
open    O
subset    O
of    O
the    O
complex    O
plane    O
C    O
,    O
and    O
"    O
f    O
"    O
:    O
"    O
U    O
"    O
→    O
C    O
is    O
a    O
holomorphic    O
function    O
,    O
then    O
"    O
f    O
"    O
has    O
an    O
antiderivative    B-Calculation105802185
"    O
F    O
"    O
on    O
"    O
U    O
"    O
,    O
and    O
the    O
value    O
of    O
every    O
line    B-Calculation105802185
integral    I-Calculation105802185
in    O
"    O
U    O
"    O
with    O
integrand    O
"    O
f    O
"    O
depends    O
only    O
on    O
the    O
end    O
points    O
"    O
u    O
"    O
and    O
"    O
v    O
"    O
of    O
the    O
path    O
,    O
and    O
can    O
be    O
computed    O
as    O
"    O
F"("v    O
"    O
)    O
-    O
"    O
F"("u    O
"    O
)    O
.    O

The    O
inner    O
level    O
(    O
next    O
-    O
to    O
-    O
last    O
line    O
)    O
defines    O
"    O
gring"("z    O
"    O
)    O
as    O
being    O
the    O
line    B-Calculation105802185
integral    I-Calculation105802185
of    O
"    O
g"("x","y    O
"    O
)    O
over    O
the    O
circle    O
with    O
center    O
(    O
"    O
xc","yc    O
"    O
)    O
and    O
radius    O
"    O
z    O
"    O
.    O

is    O
a    O
line    B-Calculation105802185
integral    I-Calculation105802185
around    O
the    O
boundary    O
curve    O
,    O
with    O
the    O
loop    O
indicating    O
the    O
curve    O
is    O
closed    O
.    O

The    O
"    O
circulation    O
of    O
the    O
fields    O
"    O
(    O
i.e.    O
their    O
curls    O
)    O
can    O
be    O
determined    O
from    O
the    O
line    B-Calculation105802185
integral    I-Calculation105802185
of    O
the    O
fields    O
around    O
the    O
closed    O
curve    O
.    O
E.g.    O
for    O
the    O
magnetic    O
field    O

Then    O
for    O
every    O
curve    O
the    O
curve    B-Calculation105802185
integral    I-Calculation105802185
can    O
be    O
computed    O
as    O

A    O
line    B-Calculation105802185
integral    I-Calculation105802185
is    O
defined    O
for    O
functions    O
of    O
two    O
or    O
three    O
variables    O
,    O
and    O
the    O
interval    O
of    O
integration    O
is    O
replaced    O
by    O
a    O
certain    O
curve    O
connecting    O
two    O
points    O
on    O
the    O
plane    O
or    O
in    O
the    O
space    O
.    O

A    O
"    O
surface    O
integral    O
"    O
is    O
a    O
definite    O
integral    O
taken    O
over    O
a    O
surface    O
(    O
which    O
may    O
be    O
a    O
curved    O
set    O
in    O
space    O
)    O
;    O
it    O
can    O
be    O
thought    O
of    O
as    O
the    O
double    B-Calculation105802185
integral    I-Calculation105802185
analog    O
of    O
the    O
line    B-Calculation105802185
integral    I-Calculation105802185
.    O

This    O
formulation    O
of    O
the    O
linking    O
number    O
of    O
"    O
γ"1    O
and    O
"    O
γ"2    O
enables    O
an    O
explicit    O
formula    O
as    O
a    O
double    O
line    B-Calculation105802185
integral    I-Calculation105802185
,    O
the    O
Gauss    O
linking    O
integral    O
:    O

holds    O
,    O
as    O
long    O
as    O
the    O
path    B-Calculation105802185
of    I-Calculation105802185
integration    I-Calculation105802185
is    O
entirely    O
contained    O
in    O
the    O
domain    O
of    O
a    O
branch    O
of    O
the    O
integrand    O
.    O

But    O
a    O
closed    O
contour    O
in    O
the    O
punctured    O
plane    O
might    O
encircle    O
one    O
or    O
more    O
of    O
the    O
poles    O
of    O
Γ("z    O
"    O
)    O
,    O
giving    O
a    O
contour    B-Calculation105802185
integral    I-Calculation105802185
that    O
is    O
not    O
necessarily    O
zero    O
,    O
by    O
the    O
residue    O
theorem    O
.    O

It    O
can    O
be    O
thought    O
of    O
as    O
the    O
double    B-Calculation105802185
integral    I-Calculation105802185
analog    O
of    O
the    O
line    B-Calculation105802185
integral    I-Calculation105802185
.    O

Line    B-Calculation105802185
integral    I-Calculation105802185

Normally    O
in    O
the    O
calculation    O
of    O
line    B-Calculation105802185
integral    I-Calculation105802185
we    O
are    O
interested    O
in    O
calculating    O

This    O
is    O
important    O
for    O
the    O
study    O
of    O
the    O
TAAR1    O
receptor    O
,    O
as    O
while    O
numerous    O
other    O
compounds    O
are    O
known    O
which    O
act    O
as    O
TAAR1    O
agonists    O
,    O
such    O
as    O
methamphetamine    O
,    O
MDMA    O
and    O
3-iodothyronamine    B-Calculation105802185
,    O
all    O
previously    O
known    O
TAAR1    O
agonists    O
are    O
either    O
weak    O
and    O
rapidly    O
metabolized    O
(    O
endogenous    O
ligands    O
)    O
,    O
or    O
have    O
strong    O
pharmacological    O
activity    O
at    O
other    O
targets    O
(    O
amphetamines    O
,    O
thyronamines    O
)    O
,    O
making    O
it    O
very    O
difficult    O
to    O
assess    O
which    O
effects    O
are    O
due    O
to    O
TAAR1    O
activation    O
.    O

3-Iodothyronamine    B-Calculation105802185

:    O
C10AD03    O
Nicofuranose    B-Calculation105802185

Many    O
networking    O
and    O
security    O
companies    O
claim    O
to    O
detect    O
and    O
control    O
Skype    O
's    O
protocol    O
for    O
enterprise    O
and    O
carrier    O
applications    O
.    O
While    O
the    O
specific    O
detection    O
methods    O
used    O
by    O
these    O
companies    O
are    O
often    O
private    O
,    O
Pearson's    B-Calculation105802185
chi-squared    I-Calculation105802185
test    I-Calculation105802185
and    O
naive    O
Bayes    O
classification    O
are    O
two    O
approaches    O
that    O
were    O
published    O
in    O
2008    O
.    O

Pearson's    B-Calculation105802185
Chi-squared    I-Calculation105802185
test    I-Calculation105802185

Mutual    O
information    O
is    O
closely    O
related    O
to    O
the    O
log    O
-    O
likelihood    O
ratio    O
test    O
in    O
the    O
context    O
of    O
contingency    O
tables    O
and    O
the    O
multinomial    O
distribution    O
and    O
to    O
Pearson's    B-Calculation105802185
χ2    I-Calculation105802185
test    I-Calculation105802185
:    O
mutual    O
information    O
can    O
be    O
considered    O
a    O
statistic    O
for    O
assessing    O
independence    O
between    O
a    O
pair    O
of    O
variables    O
,    O
and    O
has    O
a    O
well    O
-    O
specified    O
asymptotic    O
distribution    O
.    O

The    O
chi-squared    B-Calculation105802185
goodness-of-fit    I-Calculation105802185
statistic    O
is    O
a    O
statistical    O
function    O
"    O
T"("F""n    O
"    O
)    O
,    O
corresponding    O
to    O
the    O
statistical    O
functional    O

"    O
This    O
is    O
closely    O
related    O
to    O
the    O
Pearson's    B-Calculation105802185
chi-squared    I-Calculation105802185
test    I-Calculation105802185
which    O
has    O
better    O
statistical    O
underpinning    O
.    O

The    O
chi-square    B-Calculation105802185
test    I-Calculation105802185
uses    O
as    O
its    O
criterion    O
the    O
sum    O
,    O
over    O
predefined    O
groups    O
,    O
of    O
the    O
squared    O
difference    O
between    O
the    O
increases    O
of    O
the    O
empirical    O
distribution    O
and    O
the    O
estimated    O
distribution    O
,    O
weighted    O
by    O
the    O
increase    O
in    O
the    O
estimate    O
for    O
that    O
group    O
.    O

Mutual    O
information    O
is    O
closely    O
related    O
to    O
the    O
log    O
-    O
likelihood    O
ratio    O
test    O
in    O
the    O
context    O
of    O
contingency    O
tables    O
and    O
the    O
multinomial    O
distribution    O
and    O
to    O
Pearson's    B-Calculation105802185
χ2    I-Calculation105802185
test    I-Calculation105802185
:    O
mutual    O
information    O
can    O
be    O
considered    O
a    O
statistic    O
for    O
assessing    O
independence    O
between    O
a    O
pair    O
of    O
variables    O
,    O
and    O
has    O
a    O
well    O
-    O
specified    O
asymptotic    O
distribution    O
.    O

It    O
modifies    O
the    O
Pearson    B-Calculation105802185
chi-squared    I-Calculation105802185
test    I-Calculation105802185
to    O
incorporate    O
a    O
suspected    O
ordering    O
in    O
the    O
effects    O
of    O
the    O
"    O
k    O
"    O
categories    O
of    O
the    O
second    O
variable    O
.    O

Hadamard    B-Calculation105802185
finite    I-Calculation105802185
part    I-Calculation105802185
integral    I-Calculation105802185

Popular    O
counterions    O
are    O
glycine    O
and    O
tricine    B-Calculation105802185
.    O

Incognito    B-Calculation105802185
–    O
includes    O
anonymity    O
and    O
security    O
tools    O
such    O
as    O
Tor    O
by    O
default    O

Thymectacin    B-Calculation105802185
(    O
NB-1011    O
,    O
NB-101    O
,    O
N-[[5-[(E)-2-Bromovinyl]-2'-deoxyuridin-5'-O    O
-    O
yl]](phenoxy)phosphoryl]-L    O
-    O
alanine    O
methyl    O
ester    O
)    O
is    O
an    O
anticancer    O
prodrug    O
of    O
brivudine    O
monophosphate    O
.    O

In    O
the    O
first    O
step    O
of    O
the    O
biosynthesis    O
these    O
two    O
amino    O
acids    O
are    O
combined    O
by    O
the    O
enzyme    O
arginine    O
:    O
glycine    O
amidinotransferase    O
(    O
AGAT    O
,    O
EC:2.1.4.1    O
)    O
to    O
form    O
guanidinoacetate    B-Calculation105802185
,    O
which    O
is    O
then    O
methylated    O
by    O
guanidinoacetate    O
N    O
-    O
methyltransferase    O
(    O
GAMT    O
,    O
EC:2.1.1.2    O
)    O
,    O
using    O
S    O
-    O
adenosyl    O
methionine    O
as    O
the    O
methyl    O
donor    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
guanidinoacetate    B-Calculation105802185
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
phosphoguanidinoacetate    O
.    O

There    O
are    O
yet    O
other    O
cases    O
(    O
such    O
as    O
the    O
Gaussian    B-Calculation105802185
integral    I-Calculation105802185
)    O
where    O
definite    O
integrals    O
can    O
be    O
evaluated    O
exactly    O
without    O
numerical    O
methods    O
,    O
but    O
indefinite    O
integrals    O
can    O
not    O
,    O
for    O
lack    O
of    O
an    O
elementary    O
antiderivative    O
.    O

Gaussian    B-Calculation105802185
integral    I-Calculation105802185
:    O
=    O
...    O

:    O
for    O
(    O
the    O
Gaussian    B-Calculation105802185
integral    I-Calculation105802185
)    O

Occasionally    O
,    O
an    O
integral    O
can    O
be    O
evaluated    O
by    O
a    O
trick    O
;    O
for    O
an    O
example    O
of    O
this    O
,    O
see    O
Gaussian    B-Calculation105802185
integral    I-Calculation105802185
.    O

The    O
constant    O
(    O
pi    O
)    O
has    O
a    O
natural    O
definition    O
in    O
Euclidean    O
geometry    O
(    O
the    O
ratio    O
between    O
the    O
circumference    O
and    O
diameter    O
of    O
a    O
circle    O
)    O
,    O
but    O
may    O
be    O
found    O
in    O
many    O
places    O
in    O
mathematics    O
:    O
for    O
example    O
,    O
the    O
Gaussian    B-Calculation105802185
integral    I-Calculation105802185
in    O
complex    O
analysis    O
,    O
the    O
roots    O
of    O
unity    O
in    O
number    O
theory    O
,    O
and    O
Cauchy    O
distributions    O
in    O
probability    O
.    O

L-Arginine    B-Calculation105802185
ethyl    I-Calculation105802185
ester    I-Calculation105802185


